Official Protocol Title:   A Study to Assess the Safety, Pharmacokinetics and 
Pharmacodynamic Effect of MK-5160 in Subjects with Type 
1 and Type 2 Diabetes Mellitus
NCT number:  [STUDY_ID_REMOVED]  
Document Date:  27-Feb-2017
Product:   MK -5160 1
Protocol/Amendment No.: 002-00 
MK-5160-002-00 Final Protocol 27-Feb-2017
ConfidentialTHIS PROTOCOL AND ALL OF THE INFORMATION RELATING TO IT ARE 
CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & 
DOHME CORP., 
A SUBSIDIARY OF MERCK & CO., INC., WHITEHOUSE 
STATION , NJ, U.S.A.
SPONSOR:
Merck Sharp & Dohme Corp., a subsidiary  of Merck & Co., Inc. 
(hereafter referred to as the Sponsor or Merck)
One Merck Drive
P.O. Box 100
Whitehouse Station , New Jersey , 08889-0100, U.S.A.
Protocol -specific Sponsor Contact informatio n can be found in the Investigator Trial File 
Binder (or equivalent) .
TITLE:
A Study to Assess the Safety, Pharmacokinetics and Pharmacod ynamic Effect of MK-5160 
in Subjects with Ty pe 1 and Ty pe 2 D iabetes M ellitus
IND NUMBER:   
128,128
EudraCT NUMBER:   Not Applicable 
  04M9RT 
  04W8J9
Product:   MK-5160 2
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialTABLE OF CONTENTS
1.0 TRIAL SUMMARY .................................................................................................... 9
2.0 TRIAL DESIGN .......................................................................................................... 9
Trial Design ............................................................................................................. 9 2.1
Trial Diagram ........................................................................................................ 11 2.2
3.0 OBJECTIVE(S) & HYPOTHESIS(ES) .................................................................. 13
Primary Objective(s) & Hypothesis(es) .............................................................. 13 3.1
Secondary Objective(s) & Hypothesis(es) ........................................................... 13 3.2
Exploratory Objectives ......................................................................................... 13 3.3
4.0 BACKGROUND & RATIONALE .......................................................................... 14
Background ........................................................................................................... 14 4.1
Pharmaceutical and Therapeutic Background .................................................... 14 4.1.1
Ongoing Clinical Trials ....................................................................................... 15 4.1.2
Rationale ................................................................................................................ 16 4.2
Rationale for the Trial and Selected Subject Population .................................... 16 4.2.1
Rationale for Dose Selection/Regimen/Modification ......................................... 16 4.2.2
Rationale for The Use of Comparator/Placebo ............................................ 16 4.2.2.1
Starting Dose for This Trial ......................................................................... 16 4.2.2.2
Maximum Dose/Exposure for This Trial ..................................................... 17 4.2.2.3
Rationale for Endpoints ...................................................................................... 18 4.2.3
Safety  Endpoints .......................................................................................... 18 4.2.3.1
Pharmacokinetic Endpoints ......................................................................... 19 4.2.3.2
Pharmacod ynamic Endpoints ....................................................................... 19 4.2.3.3
Planned Exploratory  Biomarker Research ................................................... 20 4.2.3.4
Future Biomedical Research ........................................................................ 21 4.2.3.5
Benefit/Risk ........................................................................................................... 21 4.3
5.0 METHODOLOGY ................................................................................................... 21
Entry Criteria ........................................................................................................ 21 5.1
Diagnosis/Condition for Entry  into the Trial ...................................................... 21 5.1.1
Subject I nclusion Criteria .................................................................................... 21 5.1.2 
  04M9RT 
  04W8J9
Product:   MK-5160 3
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialSubject Exclusion Criteria .................................................................................. 25 5.1.3
Trial Treatment(s) ................................................................................................ 30 5.2
Dose Selection/Modification .............................................................................. 31 5.2.1
Dose Selection (Preparation) ....................................................................... 31 5.2.1.1
Dose Modification (Escalation/Titration/Other) .......................................... 31 5.2.1.2
Timing of Dose Administration .......................................................................... 31 5.2.2
Trial Blinding...................................................................................................... 31 5.2.3
Randomization or Treatment Allocation ............................................................ 32 5.3
Stratification .......................................................................................................... 32 5.4
Concomitant Medications/Vaccinations (Allowed & Prohibited) .................... 32 5.5
Rescue Medications & Supportive Care ............................................................. 33 5.6
Diet/Activity/Oth er Considerations ..................................................................... 33 5.7
Diet...................................................................................................................... 33 5.7.1
Alcohol, Caffeine, Tobacco, Activity ................................................................ .34 5.7.2
Alcohol Restrictions ..................................................................................... 34 5.7.2.1
Caffeine Restrictions .................................................................................... 34 5.7.2.2
Smoking Restrictions ................................................................................... 34 5.7.2.3
Activity  Restrictions .................................................................................... 34 5.7.2.4
Contraception ............................................................................................... 34 5.7.2.5
Subject Withdrawal/Discontinuation Criteria ................................................... 34 5.8
Discontinuation of Treatment ............................................................................. 34 5.8.1
Withdrawal from the Trial .................................................................................. 35 5.8.2
Subject Replacement Strategy ............................................................................. 36 5.9
Beginning and End of the Trial ........................................................................... 36 5.10
Clinical Criteria for Early Trial Termination ................................................... 36 5.11
6.0 TRIAL FLOW CHART ........................................................................................... 37
7.0 TRIAL PROCEDURES ........................................................................................... 41
Trial Procedures ................................................................................................... 41 7.1
Administrative Procedures .................................................................................. 41 7.1.1
Informed Consent ......................................................................................... 41 7.1.1.1
7.1.1.1.1 General Informed Consent .................................................................... 41 
  04M9RT 
  04W8J9
Product:   MK-5160 4
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidential7.1.1.1.2 Consent and Collection of Specimens for Future Biomedical 
Research ................................................................................................ 42
Inclusion/Exclusion Criteria ........................................................................ 42 7.1.1.2
Subject I dentification Card .......................................................................... 42 7.1.1.3
Medical History ........................................................................................... 42 7.1.1.4
Prior and Concomitant Medications Review ............................................... 42 7.1.1.5
7.1.1.5.1 Prior Medications .................................................................................. 42
7.1.1.5.2 Concomitant Medications ..................................................................... 42
Assignment of Screening Number ............................................................... 42 7.1.1.6
Assignment of Treatment/Randomization Number ..................................... 43 7.1.1.7
Trial Compliance (Medication/Diet/Activity /Other) ................................... 43 7.1.1.8
Clinical Procedures/Assessments ........................................................................ 43 7.1.2
Laboratory  Procedures/Assessments .................................................................. 45 7.1.3
Laboratory  Safet y Evaluations (Hematology, Chemistry  and Urinaly sis)..45 7.1.3.1
Pharmacokinetic/Pharmacody namic Evaluations ........................................ 46 7.1.3.2
7.1.3.2.1 Blood Collection for Plasma MK -5160 ................................................ 46
7.1.3.2.2 Blood Collection for Glargine .............................................................. 46
7.1.3.2.3 Blood Collection for Plasma Glucose (Bedside Analy sis)................... 46
7.1.3.2.4 Blood Collection for Anti-MK- 5160 and Anti-Glargine (Insulin) 
Antibody /Immunogenicity  Assay ......................................................... 47
Planned Genetic Anal ysis Sample Collection .............................................. 47 7.1.3.3
Future Biomedical Research Samples ......................................................... 47 7.1.3.4
Other Procedures ................................................................................................ .47 7.1.4
Withdrawal/Discontinuation ........................................................................ 47 7.1.4.1
7.1.4.1.1 Withdrawal From Future Biomedical Research ................................... 47
7.1.4.1.2 Lost to Follow -up.................................................................................. 48
Subject Blinding/Unblinding ....................................................................... 48 7.1.4.2
Domiciling ................................................................................................... 49 7.1.4.3
Calibration of Critical Equipment ................................................................ 49 7.1.4.4
Visit Requirements .............................................................................................. 49 7.1.5
Screening ...................................................................................................... 49 7.1.5.1
Treat ment Period Visit ................................................................................. 49 7.1.5.2
Post-Trial ...................................................................................................... 49 7.1.5.3 
  04M9RT 
  04W8J9
Product:   MK-5160 5
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialCritical Procedures Based on Trial Objectives: Timing of Procedure ......... 50 7.1.5.4
Trial Design/Dosing/Procedures Modifications Permitted within 7.1.5.5
Protocol Parameters ..................................................................................... 51
Assessing and Recording Adverse Events .......................................................... 52 7.2
Definition of an Overdose for This Protocol and Reporting of Overdose to 7.2.1
the Sponsor .......................................................................................................... 53
Reporting of Pregnancy  and Lactation to the Sponsor ....................................... 53 7.2.2
Immediate Reporting of Adverse EventsAdverse Events and Incidents to the 7.2.3
Sponsor ............................................................................................................... 54
Serious Adverse Events ............................................................................... 54 7.2.3.1
Events of Clinical I nterest ............................................................................ 55 7.2.3.2
Evaluating Adverse Events ................................................................................. 56 7.2.4
Sponsor Responsibility  for Reporting Adverse Events ...................................... 59 7.2.5
8.0 STATISTICAL ANALYSIS PLAN ........................................................................ 59
Statistical Analysis Plan Summary ..................................................................... 59 8.1
Responsibility for Analyses .................................................................................. 60 8.2
Hypotheses/Estimation ......................................................................................... 61 8.3
Analysis Endpoints ............................................................................................... 61 8.4
Analysis Populations ............................................................................................. 62 8.5
Statistical Methods ................................................................................................ 62 8.6
Multiplicity ............................................................................................................ 64 8.7
Sample Size and Power Calculations .................................................................. 64 8.8
9.0 LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL 
SUPPLIES ................................................................................................................. 64
Investigational Product ........................................................................................ 64 9.1
Packaging and Labeling Information ................................................................ .65 9.2
Clinical Supplies Disclosure ................................................................................. 65 9.3
Storage and Handling Requirements .................................................................. 65 9.4
Discard/Destruction/Returns and Reconciliation .............................................. 65 9.5
10.0 ADMINISTRATIVE AND REGULATORY DETAILS ....................................... 66
Confidentiality ....................................................................................................... 66 10.1
Confidentiality  of Data ....................................................................................... 66 10.1.1
Confidentiality  of Subject Records ..................................................................... 66 10.1.2 
  04M9RT 
  04W8J9
Product:   MK-5160 6
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialConfidentiality  of Investigator Information ........................................................ 66 10.1.3
Confidentiality  of IRB/IEC I nformation ............................................................. 67 10.1.4
Compliance with Financial Disclosure Requirements ....................................... 67 10.2
Compliance with Law, Audit and Debarment ................................................... 67 10.3
Compliance with Trial Registration and Results Posting Requirements ........ 69 10.4
Quality Management System ............................................................................... 69 10.5
Data Management ................................................................................................ .69 10.6
Publications ........................................................................................................... 70 10.7
11.0 LIST OF REFERENCES ......................................................................................... 71
12.0 APPENDICES ........................................................................................................... 72
Merck Code of Conduct for Clinical Trials ........................................................ 72 12.1
Collection and Management of Specimens for Future Biomedical 12.2
Research ................................................................................................................. 74
Approximate Blood/Tissue Volumes Drawn/Collected by Trial Visit and 12.3
by Sample Types ................................................................................................... 78
12-Lead Electrocardiogram Abnormality Criteria ........................................... 79 12.4
Algorithm for Assessing Out -of-Range Laboratory Values ............................. 82 12.5
Criteria for Classifying Documented Episodes of Hyper -or Hypoglycemia 12.6
as Adverse Events ................................................................................................ .83
13.0 SIGNATURES ........................................................................................................... 84
Sponsor's Representative ..................................................................................... 84 13.1
Investigator ............................................................................................................ 84 13.2 
  04M9RT 
  04W8J9
Product:   MK -5160 7
Protocol/Amendment No.: 002-00 
MK-5160-002-00 Final Protocol 27-Feb-2017
ConfidentialLIST OF TABLES
    
Table 1  Trial Design ................................
.............................................................................. 12
Table 2  Summary  of preliminary  results from MK5160 -P001. ............................................. 15
Table 3 Trial Treatment ......................................................................................................... 30
Table 4 Sample Allocation Schedule ..................................................................................... 32
Table 5  Laboratory  Tests ....................................................................................................... 45
Table 6  PK (Blood) Collection Windows ................................
.............................................. 50
Table 7  Evaluating Adverse Events ....................................................................................... 57
Table 8  Probability  of Supporting Primary  PD Hy pothesis ................................................... 60
Table 9  Probability  of Supporting Primary  PD Hy pothesis ................................................... 64
Table 10  Product Descriptions ............................................................................................... 65 
  04M9RT 
  04W8J9
Product:   MK -5160 8
Protocol/Amendment No.: 002-00 
MK-5160-002-00 Final Protocol 27-Feb-2017
ConfidentialLIST OF FIGURES
Figure 1 Overal l Trial Design ................................
................................................................ 11
Figure 2   Study  Design ................................ ................................ ................................ ........... 12 
  04M9RT 
  04W8J9
Product:   MK-5160 9
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidential1.0TRIAL SUMMARY
Abbreviated Title Multiple ascending dose study of MK-5160 in subjects with Type 1 
and Type 2 diabetes mellitus
Sponsor Product Identifiers MK-5160
Trial Phase Phase 1
Clinical Indication Diabetes mellitus
Trial Type Interventional
Type of control Placebo and a ctive control w ithout placebo
Route of administration Subcutaneous
Trial Blinding Double -blind
Treatment Groups Part 1 (T1DM): 
MK-5160 16 nmol/kg or glargine 0.4 U/kg
MK-5160 32 nmol/kg or glargine 0.4 U/kg
MK-5160 </= 64 nmol/kg or glargine 0.4 U/kg
Part 2 (T2DM):
MK-5160 16 nmol/kg or glargine 0.6 U/kg
MK-5160 32 nmol/kg or glargine 0.6 U/kg
MK-5160 </= 64 nmol/kg or glargine 0.6 U/kg
Number of trial subjects Approx imately 48subjects w ill be enrolled.
Estimated duration of trial The Sponsor estimates that the trial will require approximately 8 
months from the time the first subject signs the informed consent until 
the last subject’s last study -related phone call or visit.
Duration of Participation Each subject will participate in the trial for approximately 6-8weeks 
from the time the subject signs the Informed Consent Form  (ICF) 
through the final contact.  After a washout phase of 4 days each 
subject will be receiving assigned treatment for approximately 2
weeks.  After the end of treatment each subject will be follow ed for 19 
days.
2.0TRIAL DESIGN
Trial Design 2.1
This is a randomized , active- and placebo -controlled, parallel -group, single -site, double -blind
trialof MK- 5160 in subjects with type 1 and t ype 2 diabetes mellitus (DM) .
This is a two -parttrial, with three panels per part.  Type 1 diabetes mellitus ( Part1) and Ty pe 
2 DM (Part 2) subjects will be given daily  fixed doses of MK-5160 or glargine (active 
comparator )in three predefined , increasing doses in each panel.  The first panel in Part 1 will 
be the initial panel; the second panel in Part 1 and first panel in Part 2 will be initiated after 
review of preliminary  safety and pharmacod ynamics from the initial panel .  Different 
subjects will participate in each panel.
T2DM subjects in Part 2may be on a single anti-hypergl ycemic agent (AHA) of a 
permissible class (metformin, DPP4 inhibitor , sulfonylurea, or alpha -glucosidase inhibitors ) 
ormetformin in combination with one additional permissible AHA (a DPP4 inhibitor , 
sulfony lurea, or alpha -glucosidase inhibitor) , at stable doses for at least 8 weeks prior to 
screening .  Subjects may also be on insulin in addition to the above , or on insulin alone .  Randomization Ratio 3:1 (MK -5160/glargine) 
  04M9RT 
  04W8J9
Product:   MK -5160 10
Protocol/Amendment No.: 002-00 
MK-5160-002-00 Final Protocol 27-Feb-2017
ConfidentialSubjects taking metformin and/or a DPP-
4 inhibitor will continue these medications at their 
pre-enrollment doses throughout study  participation , but subjects taking a sulfony lurea or an 
alpha -glucosid ase inhibitor will discontinue the sulfony lurea or alpha -glucosidase inhibitor at 
screening, at least 7 days prior to CRU admission, and remain off until the completion of 
dosing.  
All subjects would be brought into the site on Day -4, place d on continuous glucose 
monitoring (CGM ), and started on an appropriate dose of fast-acting insulin , to be
administered via a subcutaneous (SC) pump that will remain in place for the duration of 
dosing . 
 The SC pump will be placed in all subjects during the washout period with the 
exception of non-insulin requiring T2DM subjects.  Subjects will be domiciled for the 
entirety  of MK-5160/glargine dosing, receiving standard meals and snacks.  Prandial and 
(if 
needed) rescue insulin will be dosed throughout the trial according to standard clinical 
practice and at the discretion of the investigator , taking both the pre-prandial glucose level 
(fingerstick) and the carbohy drate content of the planned meal into account.  In addition, 
subjects will have fingerstick glucose levels checked prior to bedtime and once overnight , 
and as needed per the subject and/or Investigator .  
On Day -1, the insulin via the SC pump will be discontinued, and subjects will be fasted 
overnight while also receiving insulin an d dextrose via IVinfusions, as needed, to set plasma 
glucose levels at 100 mg/dL  prior to dosing and clamp initiation .  On Day 1, subjects will be 
administered MK-5160 or glargine (3:1) SC.  Subjects will be blinded in a double -dummy 
fashion, so that each subject will get two injections, one of which would be placebo .  
Subjects would continue to be on CGM ,but will also be on a eugly cemic clamp (fasted) for 
~24 hours after this first dose.   After completion of the euglycemic clamp, subjects will 
restart the standardized diet and continue to receive daily SC MK-5160/glargine at the same 
dose, with continued prandial insulin at the dosing discretion of the investigator via the SC 
pump.   If necessary  to treat hypergl ycemia, subjects may also receive bolus and/or infused 
insulin via the SC pump , at the discretion of the Investigator .
On Day 7, subjects will not be given an evening meal or a pre-bedtime snack, while 
continuing to be domiciled and on CGM.  A  “ pre-dinner ” glucose measurement will be 
obtained, and hypergl ycemia will be corrected if necessary , but subjects will then initiate a 
fast.  By not taking the evening meal and snack on Day 
7, subjects will be exposed to a 
fasting stress to assess the extent of nighttime hypogly cemia, while the subjects continue to 
be closely monitored.  Hypogl ycemia (and hypergly cemia) , if observed, will be treated as 
outlined in Appendix 12.6,at the discretion of the Investigator according to the site’s 
stand
ard operating procedures.  If the individual subject does not require intervention for 
hypoglycemia after this Day 
7 fast, a similar fasting will occur for that subject on Day 9.  
Subjects will have a normal meal schedule on Day 8, and on Day s 10-
11.
MK-5160 is expected to be at steady -state prior to Day 12.  On the evening of Day 11, 
subjects will be fasted overnight on insulin and dextrose IV infusions, and then given MK-
5160/glargine on a euglycemic clamp, as on Day 1.  This clamp may continue beyond 24 
hours, to assess duration of action.  After completion of this clamp, subjects 
will restart the 
standardized diet but also restart their home insulin regimen.  Subjects will be discharged 
from site ~48 hours after the final clamp, when glucose levels are stable. 
  04M9RT 
  04W8J9
Product:   MK-5160 11
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialIn addition to the extensive glucose monitoring (CGM, euglycemic clamp, pre-prandial and 
overnight assessment), subjects will be evaluated for the effects of MK-5160/glargine on 
lipid metabolism and ketogenesis.  Fasting p lasma levels of free f atty acids (FFA, also known 
as NEFA), glycerol, and triglycerides, as well as beta-hydroxy butyric acids (BHA) will be 
collected throughout the trial.
Subjects will have intense pharmacokinetic (PK)sampling during the clamps, with daily 
sampling at other times during dosing and up to one week after dosing .  Vital signs and 
ECGs will be collected at specified times throughout the trial, especially  during anticipated 
steady  state of MK-5160 .  Safety  laboratory  studies will be obtained predose, after the first 
dose (during the clamp), at steady  state and after completion of the dosing.  Anti-drug 
antibodies (ADA) will also be collected pre -dose and after completion of treatment .
Specific procedures to be performed during the trial, as well as their prescribed times and 
associated visit windows, are outlined in the Trial Flow Chart -Section 6.0. Details of each 
procedure are provided in Section 7 .0–Trial Procedures.
Because this is a Phase Iassessment of MK-5160 in humans, the pharmacokinetic, 
pharmacod ynamic and safet y profiles of the compound are still being elucidated. This 
protocol is therefore written with some flexibility  to accommodate the inherent dynamic 
nature of Phase I clinical trials. Please refer to Section 7.1.5 –Visit Requirements for 
examples of modifications permitted within the protocol parameters.
Trial Diagram 2.2
The trial /study design is depicted in Figure 1, Figure 2andTable 1.
Part 1 will start first, and initiation of Part 2 will occur after review of preliminary  safety  and 
pharmacod ynamic results from the first panel in Part 1.  Subjects will participate in only one 
panel.   Subjects will get injections of MK-5160/glargine and placebo matched to the 
alternative active treatment .
Figure 1Overall Trial Design  
 
  04M9RT 
  04W8J9
Product:   MK-5160 12
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialThe general overall plan is depicted.  After admission to the CRU , subjects will discontinue 
their home diabetes regimen (including insulin) and be placed on continuous glucose 
monitoring (CGM) and a SC insulin pump to control glucose (if needed ).  On Day -1, this 
will be converted to IV infusions of insulin and dextrose to set plasma glucose for dosing and 
first clamp on Day 1.  After 24 hours, the clamp will be discontinued and subjects will 
resume a normal diet on MK5160/glargine.  On Days 7 and 9, subjects will be partially  
fasted.  On Day  12, subjects will undergo a second clamp for up to 30 hours, and restart their 
home regimen.  Subjects will continue to be domiciled and observed on the home regimen, 
with continued pharmacokinetic assessment.
Figure 2  Study  Design
Table 1Trial Design
Part1
(T1DM)Panel AaPanel B Panel C
MK-5160 16 nmol/kg or 
glargine 0.4 U/kgMK-5160 32 nmol/kgbor 
glargine 0.4 U/kgcMK-5160 ≤64nmol/kgbor 
glargine 0.4 U/kgc
Part2
(T2DM)Panel D Panel E Panel F
MK-5160 16 nmol/kgb or 
glargine 0.6 U/kgcMK-5160 32 nmol/kgbor 
glargine 0.6 U/kgcMK-5160 ≤64nmol/kgbor 
glargine 0.6 U/kgc
aWithin each treatment panel , 6subjects will be randomized to receive MK-5160 and 2subjects to receive glargine
according to a com puter -generated allocation schedule.  In addition to MK -5160 or glargine, subjects will also receive 
placebo (i.e., subjects receiving MK-5160 will also receive placebo matched to glargine, and subjects receiving 
glargine will alsoreceive placebo matched to MK -5160).
bThe suggested doses may be adjusted downward based on evaluation of safety, tolerability, pharmacokinetic and/or 
pharmacodynamic data observed in previous treatment periods.
cThe suggested glargine doses may be adjusted downward or upward, based on evaluation of pharmacodynamic s data 
observed in previous treatment periods
 
  04M9RT 
  04W8J9
Product:   MK-5160 13
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidential3.0OBJECTIVE(S) & HYPOT HESIS(ES)
Primary Objective(s) & Hypothesis (es) 3.1
1)Objective:   To evaluate the safet y of multiple SC doses of MK -5160 in adult subjects 
with T1 and T2 DM.
2)Objective: To determine the maximal glucose infusion rate required to maintain 
target glucose levels in a euglycemic clamp setting (GIRmax) ofMK- 5160 in adult 
subjects with T1 and T2 DM at stead y-state following SC dosing.
Hypothes is: At a dose with sufficient safet y, the mean stead y-state maximum level of 
GIR (GIRmax) after MK-5160 administration in both T1 and T2 DM patients is 
between 1.5 and 4.5 mg/kg/min.
Secondary Objective(s) & Hyp othesis(es) 3.2
1)Objective : To estimate the plasma PK profile (e.g. Cmax, Css, Steady  State AUC0 -
24hr, CL, Tmax) of MK -5160 after SC administration.
Exploratory Objectives 3.3
1)Objective: To explore the levels of plasma triglycerides (TG), FFA and glycerol 
after SC doses of MK -5160 compared to glargine, in order to assess the effect of MK -
5160 on lipoly sis.
2)Objective: To explore the effect of MK-5160 on fasting morning glucose after SC 
doses of MK-5160 compared to glargine, as a secondary  analysis for the effect of 
MK- 5160 on glucose metabolism.
3)Objective: To assess the relationship between PK parameter values of MK-5160 
with BMI after SC administration.
4)Objective: To explore the incidence and nature of nighttime and other episodes of 
potential hy poglycemia, using fingerstick glucose levels and CGM data.
5)Objective:  To explore possible changes in counter regulatory  hormones (e.g., 
glucagon) after treatment with MK -5160.
6)Objective: To explore the relationship betwee n exposure and subdivisions of GIR
(i.e., GIR AUC0 -24, AUC0 -12, AUC12 -24, AUC24 -end of clamp [for final clamp] )
after one dose and at steady  state .
7)Objective: To explore the relationship between daily  non-basal insulin requirements 
(prandial and any corrective doses given ) inMK- 5160 vs. glargine treatment.
8)Objective: To explore the relationship between genetic variation and response to the 
treatment(s) administered , and mechanism sof disease .  Variation across the human 
genome may  be anal yzed for association with clinical data collected in this study . 
  04M9RT 
  04W8J9
Product:   MK-5160 14
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidential4.0BACKGROUND & RATIONA LE
Background 4.1
Refer to the Investigator’s B rochure (IB) for detailed background information on MK- 5160 .
Pharmaceutical and Therapeutic Background 4.1.1
Diabetes mellitus (Type 1 and Type 2; T1DM, T2DM) is a global public health issue 
believed to affect over 400 million individuals worldwide in 2015, and is estimated to affect 
almost 650 million by  2040 . Currently  nearly 10% of the U .S. population is directly  affected 
by the disease , and by 2050 it is estimated that 1 in 3 Ame rican adults will have diabetes.  
According to CDC statistics, 14% of all diabet ics in the U.S. are on insulin alone, and 
another 13% are on a combination of insulin and oral therap y.  All insulin -treated patients 
utilize basal insulin , which is intended to maintain normal plasma glucose levels during 
fasting. 
Although insulin has been a mainstay  of diabetes therapy  for decades, exogenousl y 
administered insulin poses short -term risks and long-term drawbacks.  Excessive basal 
insulin leads tohypoglycemia , followed by several day s ofdose adjustment to achieve a new 
steady -state respo nse. Practitioners and patients often settle at moderate under- dosing of 
basal insulin, mitigating therisk for hypoglycemia at the expense of notachieving target 
glycemic levels and thereby  increasing the risk of long term complications of diabetes.  
The goal of the Insulin Receptor Partial Agonist (IRPA) program is to develop a novel, once -
daily  SC basal insulin with a wide therapeutic index (TI), permitting more aggressive 
treatment to the glycemic target with reduced risk of hypoglycemia.  The improv ed TI of an 
IRPA would significantly reduce the risk of hypoglycemia relative to available therapies, 
thus allowing more confidence for practitioners and patients to dose -titrate IRPA to attain 
target goals for control of fasting glucose.   An IRPA is expec ted to have hepato -adipose 
preferentiality  as a result of greater activation of insulin receptors in those tissues relative to 
skeletal muscle.
A generally  accepted surrogate for measurement of the physiologic response to insulin with 
respect to glucose lowering is the eugly cemic clamp procedure, in which subjects are given a 
fixed dose of insulin ,and plasma glucose levels are set to a target level using a variable 
glucose infusion.  Several previous studies have demonstrated that inhibition of hepatic 
glucose production corresponds to a glucose infusion rate (GIR) of 1.5-2.0 mg/kg/min in the 
euglycemic clamp.  Inhibition of lipoly sis at doses leading to GIRs in this range would 
support a hepato -adipose preferential activity . 
  04M9RT
CCI 
  04W8J9
Product:   MK-5160 15
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialOngoing Clinical Trials 4.1.2
MK- 5160 -001 (P001) is an active- controlled and placebo -controlled, single- site, three -part
trial of MK- 5160 in healthy  adult subjects which is completed with ongoing data assessment . 
P001 is being conducted to assess the initial clinical safet y, tolerability , PK and 
pharmacod ynamics (PD)of MK-5160 following administration to humans.  PK after both IV 
and SC administration is being assessed.  PD is being assessed by evaluating the glucose 
infusion rate (GI R) after administration of MK -5160 under eugl ycemic clamp conditions , and 
by assessi ng plasma free fatty acid (FFA) and glycerol levels .  In addition, the potential 
antagonistic effect of MK-5160 on rapid -acting insulin isbeing assessed, also under 
euglycemic clamp conditions.
To date a total of 88subjects have been enrolled. Approximat ely 63subjects have been dosed 
with MK-5160 , which has been generall y well tolerated .  Adverse events (AEs), vital signs, 
exams, ECGs and laboratory safet y studies have been generall y unremarkable.  
 
  
These results support hepato -adipose preferential activity  of MK-5160, which further 
supports testing of MK -5160 as a novel basal insulin in T1 and T2DM patients . 
  04M9RT
CCI
CCI
CCI
CCI 
  04W8J9
Product:   MK-5160 16
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialRationale 4.2
Rationale for the Trial and Selected Subject Population 4.2.1
This study  is being conducted to assess the safety , tolerability , PK and PD of MK-5160 
following administration to patients with type 1 diabetes (T1DM) and type 2 diabetes 
(T2DM). PK in both T1DM and T2DM subjects will be assessed. PD, as GIR, will be 
assessed using a euglycemic clamp in T1DM and T2DM subjects after the first dose and at 
steady -state after SC dosing of MK-5160. In addition, plasma FFA and glycerol levels will 
be assessed to understand PD with respect to lipoly sis.
The acceptable GIRmax is derived from the target GIRmax of 1.5-2.0 mg/kg/min, which 
reflects inhibition of hepatic glucose production, with the upper limit (4.5 mg/kg/min) 
reflecting the maximum observed GIR in studies of the hepato -preferential peglispro. PD 
will also be assessed by examining fasting morning glucose levels after administration of
standard of care (SOC )or MK-5160, and other PD endpoints will include variability  of 
glucose level s, as determined by CGM, and inhibition of lipoly sis.
Rationale for Dose Selection/Regimen /Modification 4.2.2
Rationale for The Use of Comparator/Placebo 4.2.2.1
Glargine (U100) will be administered as a comparator for MK-5160.  Subjects will be 
randomized to receive glargine or MK-5160 in both parts . The use of glargine is to confirm 
the PD profile of glargine compared to MK-5160 in this population, and to serve as a safet y 
comp arator for MK-5160.  PD will be assessed as the GIR required to maintain the 
prespecified eugly cemic clamp (100 mg/dL ).  In addition to PD, glargine will be used as a 
comparator for safet y –for AEs and for laboratory  and other safet y markers –against MK-
5160.
Glargine will be administered at a dose of 0.4 U/kg in Part 1 (T1DM subjects), as this dose 
leads to a GIR of ~1.5 mg/kg/min in a euglycemic clamp study  of T1DM subjects [1].  To 
account for insulin resistance in the T2DM population, the dose in Part 2 will be 0. 6 U/kg. 
To facilitate blinding , each subject will get two injections at each administration timepoint .  
Subjects will be dosed with MK- 5160 and placebo matched with glargine, or glargine and 
placebo matched to MK -5160 .
Starting Dose for This Trial 4.2.2.2
In the diabetic patient populations to be studied in this trial, the lowest dose of MK-5160 
should be an effective dose to reduce the likelihood of hypergl ycemia and its associated 
complications.  Note that all patients will be domiciled and closely monitored throughout the 
trial, and that T1DM patients will also be receiving prandial insulin reflective of intake and 
pre-prandial plasma glucose, in accordance with stand ard clinical practice .  This will reduce 
the likelihood of hypergly cemia.   In addition, the Investigator has discretion to administer 
corrective fast -acting insulin via the SC pump, either as a bolus or as an infusion.
The proposed starting dose of MK-5160 in this trial is 16.0 nmol/kg SC daily  for 12 days, in 
both the T1DM and T2DM parts .    
  04M9RT
CCI 
  04W8J9
Product:   MK-5160 17
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialThe projected stead y-state AUC 0-24hr for a daily dose of 16 nmol/kg is 31 nM*hr .  
 
  Thus, the NOAEL was set at the dog 
exposure of 814 nM*hr, which sets a margin of 26x for this initial dose of 16 nmol/kg SC.  
 
 
 
The expected accumulation of MK-5160 after SC administration is such that the stead y state 
AUC0 -24hr of 31 nM*hr is expected to be reached ~ 7 days.  
 
 
 
 
 
The first panel of Part 1 (T1DM) will be dosed initially .  Dosing for the first panel of Part 2 
will commence after at least four subjects have completed dosing, and a review of available 
preliminary  safety data and initial pharmacod ynamic data is completed .  The decision to 
initiate Part 2 and proceed in Part 1 will be made by both the Investigator and Sponsor, after 
review of the available data , and will be communicated via a letter to the investigator.
Maximum Dose/Exposure for This Trial 4.2.2.3
 
 
  Subjects in this trial will be domiciled and 
closely  monitored.  Moreover, the overall intent of this trial is to maintain plasma glucose 
levels in the normal physiologic range .  Asdirected by the CTA Guidance [ICH Topic M3 
(R2)], the maximum allowable exposure inthis trial is the lower exposure (AUC) in either 
species at the highest dose tested, as neither species demonstrated toxicity  not related to the 
pharmacological activity  of MK -5160, and at least 3 dose levels were assessed in both.   
The projected dose range for MK-5160 after daily  SC administration has been estimated,
based onP001, preclinical studies and extensive modeling. The maximum proposed dose in 
both T1DM and T2DM subjects is 64nmol/kg SC daily , which is projected to lead to a 
steady  stateexposure (AUC0 -24hr) of 124nM*hr .   
  04M9RT
CCI
CCI
CCI
CCI
CCI
CCI 
  04W8J9
Product:   MK-5160 18
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidential  
An anticipated insulin resistance of ~1.5-2x in T2DM subjects would lead to an equivalent 
effect of ~½ of the above nM*hr in healthy  subjects or T1DM subjects, which is equivalent 
to the insulin to be delivered at 32 nmol/kg in those subjects.   
 
 
 
 Thetop dose in the trial may be decreased if results from the first 
two panels show satisfactory GIR and glucose lowering.
 
 
 
 
Subjects in this trial will be 
receiving a glucose infusion via theeugly cemic clamp on Day 1 and at steady  state, and will 
be closel y observed and frequently  monitored for the duration of dosing and after 
discontinuation of the steady -state clamp.
Rationale for Endpoints 4.2.3
Safety Endpoints 4.2.3.1
As this is an early  clinical investigation of MK-5160 , safet y will be carefully monitored. 
Physical examinations, vital signs, 12-lead electrocardiograms (ECG), laboratory safety  tests 
(serum chemistry , hematology , and urinal ysis) and monitoring of adverse experiences (AEs) 
will be assessed throughout the dosing intervals ,with assessment collection times optimized 
based on the expected PKproperties of MK-5160 .  
. Specific restrictions are set forth in the inclusion and exclusion criteria 
regarding blood pressure, potassium levels , magnesium levels, and ECG findings, where only 
normal findings are acceptable for inclusion of subjects (see Section 5, Methodology , for 
details). Additional monitoring of potassium levels at the bedside may be performed at the 
discretion of the investigator.   Additionally , due to the fluid load required for a clamp 
procedure, normal blood pressure and renal function will be required from a safety  
standpoint. Vital signs and ECG readings will beperformed throughout the study  to monitor 
any potential untoward effects (see Section 6.0, Trial Flow Chart, for details).  Subject 
discontinuation criteria for QTc abnormalities have been defined (see Section 5.8and 12.4 
for details). Standard chemistry , hematology  and urinalysis panels will be assessed along 
with careful and frequ ent glucose monitoring .
MK- 5160 administration could lead toanti-drug antibod y (ADA) formation .  
 
 
ADA and AIA will be assessed pre -dose and at 14 and 28 day s post dose (see section 7.1.5.3. 
  04M9RT
CCI
CCI
CCI
CCI
CCI 
  04W8J9
Product:   MK-5160 19
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidentialfor post-trial follow -up).  Drug -induced p ositive ADA and AIA will be further evaluated for 
neutralizing activit y.
Pharmacok inetic Endpoints 4.2.3.2
The PD endpoint will be coupled with plasma MK-5160 concentration, to help assess the 
time-action profile for SC administration of MK-5160.  In addition, Cmaxand Tmax,plasma 
exposures (AUC 0-24hr) and additional plasma concentration parameters (C24hr) will also be 
measured, as will apparent terminal half-life (t1/2) reflective of the absorption half-life after 
SC administration.
Pharmacodynamic Endpoints 4.2.3.3
The primary  objective in this study , in addition to evaluation of safety , is to gain an
understanding ofthepharmacod ynamic effect of MK- 5160, as this will predict theability  of 
MK- 5160 to function as a hepato -adipose selective basal insulin. Evaluation of glucose 
lowering, as GIR in the eugly cemic clamp and as measurements in conti nuous glucose 
monitoring, in addition to evaluation of lipoly sis will be key to understanding MK -5160.
Evaluation under euglycemic clamp conditions protects subjects from hypogly cemia, and 
allows a quantitative and comparable determination of PD. At euglycemia, full agonist 
insulins such as RHI require amaximum GIR of approximately  10-11 mg/kg/min to prevent
hypoglycemia, reflecting a combination of suppressed hepatic glucose production and
insulin -mediated glucose disposal, primarily  into muscle.  
Previous studies have 
demonstrated that hepatic glucose production corresponds to a GIR of 1-2 mg/kg/min, while
activation of muscle glucose uptake corresponds with GIRs of greater than 4 mg/kg/min 
[5,6]. GIRs between 2 and 4 mg/kg/min are attributed to inhibition of hepatic glucose uptake,
in addition to changes in tissue -specific glucose utilization. Of note, thehepatoselective 
insulin peglispro leads to amaximum GIR of ~4 mg/kg/min [7
] which included a mild effec t 
on presumed muscle uptake. Thus, MK-5160 GIR should predict tissue selectivity , and in the 
proposed trial a hepatopreferential activity can be evaluat ed in T1 and T2DM patients .
In general, the concentration of insulin is thought to be the primary  driver for GIR in the 
euglycemic clamp.  As an exploratory  analysis, the relationship between exposure, as well as 
subdivisions of exposure (AUC0 -24, AUC0 -12,AUC12 -24), with GIR will be examined.
Evaluation of the ability of MK-5160 to inhibit lipoly sis will be critical, as the results of 
peglispro trials suggest that the hepatic effects of insulin alone result in accumulation of liver 
triglyceride and elevate d aminotransferases.   
 
fasting plasma FFA
(non-esterfied fatty acids -NEFA) and glycerol will be evaluated in this trial to assess the 
effect of MK-5160 on lipoly sis, and in this trial serum triglycerides will also be assessed , as 
an effect on trigl ycerides may be more apparent after the extended dosing .  
Inhibition of ketogenesis is an additional important desirable effect of an ideal basal insulin, 
and as this is almost exclusively  a hepatic process, it would be expected that MK -5160 would 
inhibit ketogenesis.   
  04M9RT
CCI
CCI
CCI 
  04W8J9
Product:   MK-5160 20
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidential 
  To assess 
ketosis, β -hydroxybutyratewill be assessed. 
NEFA, glycerol, and β-hydroxybutyrate will be correlated with MK-5160 PK andglucose 
PD to more fully  understand the complete PD profi le for MK- 5160.
GIR will be adjusted to maintain plasma glucose levels 100 mg/dL . After and during the 
dosing of MK-5160 or glargine , glucose levels will bemonitored at the bedside and the GIR 
will be adjusted accordingl y. To address the primary  hypothesi s around GIR, the values of 
interest are the individual maximal GI R (GI Rmax) values at steady  state, which is anticipated 
to fall between 1.0-2.0 mg/kg/min . As detailed below 
(Section 8), the GIRmax values at steady  state will comprise the analysis. Within each panel, 
glargine will be given to two of the subjects who have been randomized along with the six 
subjects being given MK -5160 .
In addition to the key endpoints noted above, additional exploratory endpoints will be 
examined to achieve a richer understanding of the actions of MK-5160 in diabetic patients.  
Along with the analy sis of GIR noted above, data on morning fasting glucose will be 
collected, as will extensive data on glucose levels using CGM.  These data will be closely  
examined during the longer fasting periods during the trial, to explore the degree to which 
plasma glucose levels fall during prolonged fasting while subjects are on MK-5160 or 
glargine.  This will aid in understanding the potential risk of MK-5160 to lead to 
hypoglycemia.  As noted, the subjects will be carefull y monitored for symptomatic 
hypoglycemia and for glucose levels requiring intervention. 
MK- 5160 will be administered to T2DM patients, who generally  are overweight to obese and 
thus have increased subcutaneous tissue that may complicate absorption and thus lead to 
variability  in PK.  It is anticipated that the T2DM subjects enrolled in this trial will cover a 
range of BMI, and thus PK with respect to BMI will be examined.  
Additional exploratory  analysis includes an examination of the effects of MK-5160 and 
glargine on counterregulatory  hormones –specifically , glucagon.  Hypogly cemia results in 
elevation of glucagon levels in non-diabetic patients, but this response is often blunted or 
absent in T1DM patients (and some T2DM patients), likely  due to the action of insulin on 
glucagon- secreting alpha cells.  MK-5160 may not have this effect on alpha cells, due to the 
tissue selectivity ,and thus plasma glucagon levels will be measured when plasma glucose 
levels are expected to be low.  
Planned Exploratory Biomarker Research 4.2.3.4
Planned Genetic Analysis
Understanding genetic determinants of drug response and the molecular basis of disease is an 
important endeavor during medical research. This research will evaluate whether genetic 
variation within a clinical trial population correlates with response to the treatment(s) under 
evaluation and/or disease . If genetic variation is found to predict efficacy  or adverse events, 
the data might inform optima l use of therapies in the patient population. Knowledge of the 
molecular basis of disease contributes to the development of novel biomarkers and the 
identification of new drug targets. This research contributes to understanding molecular basis 
  04M9RT
CCI
CCI 
  04W8J9
Product:   MK-5160 21
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidentialof disease and the genetic determinants of efficacy and safet y associated with the treatments 
in this study .
Future Biomedical Research 4.2.3.5
The Sponsor will conduct Future Biomedical Research on specimens consented for future 
biomedical research during this clinical trial.  This research may include genetic anal yses 
(DNA), gene expression profiling (RNA), proteomics, metabolomics (serum, plasma) and/or 
the measurement of other analytes, depending on which specimens are consented for future 
biomedical research.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main trial) and will only be conducted on specimens from 
appropriatel y consented subjects. The objective of collecting /retaining specimens for Future 
Biomedical Research is to explore and identify  biomarkers that inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such informa tion to develop safer, more effective drugs /vaccines , and/or to ensure that 
subjects receive the correct dose of the correct drug /vaccine at the correct time.  The details 
of this Future Biomedical Research sub-trial are presented in Section 12.2 –Collect ion and 
Management of Specimens for Future Biomedical Research.
Benefit/Risk 4.3
It cannot be guaranteed that subjects in clinical trials will directly  benefit from treatment 
during participation as clinical trials are designed to provide information about the safety  and 
effectiveness of an investigational medicine.
Additional details regarding specific benefits and risks for subjects participating in this 
clinical trial may be found in the accompanying Investigators Brochure (IB) and Informed 
Consent documents.
5.0METHODOLOGY
Entry Criteria 5.1
Diagnosis/Condition for Entry into the Trial 5.1.1
Male/Female subjects with T1DM or T2DM between the ages of 18and 60or 65years
(inclusive , respectivel y)will be enrolled in this trial.
Subject Inclusion Criteria 5.1.2
In order to be eligible for participation in this trial, the subject must:
For Part1(T1DM) :
1. Subjects provide written informed consent/assent for the trial. The subject may also 
provide consent/assent for Future Biomedical Research.  However, the subject may
participate in the main trial without participating in Future Biomedical Research. 
  04M9RT 
  04W8J9
Product:   MK -5160 22
Protocol/Amendment No.: 002-00 
MK-5160-002-00 Final Protocol 27-Feb-2017
Confidential2.Be male, or female of non -childbearing potential between 18 to 60 years of age at the 
pre-
trial (screening) visit.
A female of non -childbearing potential is defined as: 
a.A female who is postmenopausal without menses for at least 1 year and has a 
follicle stimulating hormone (FSH) value in the postmenopausal range upon 
pretrial (screening) evaluation,
b.A female who is status post hy sterectomy , oophorectomy  or tubal ligation.  
i. NOTE: These procedures must be confirmed with medical records. In 
the absence of documentation, hysterectom y may be confirmed by 
pelvic exam or if necessary  by ultrasound; oophorectom y may be 
confirmed by hormone levels, particularl y FSH in the post-menopausal 
range, but tubal ligation subjects without records should be excluded.  
Information must be captured appropriately  within the site's source 
documents
3.Be judged to be in good health based on medical history , physical examination, vital 
sign measuremen ts, ECG, and laboratory  safety tests (Section 7.1.3.1) performed at 
pretrial (screening) and prior to administration of the initial dose of trial drug. 
Appendix 12.4 provides a table of 12-Lead Electrocardiogram Abnormality  Criteria 
and Appendix 12.5 provides an algorithm for the assessment of out-of-range 
laboratory  values. Subjects with the following conditions may  be enrolled:
a.Hypertension treated with lifesty le modification alone or stable doses (no change 
for ≥3 months) of ≤2 antihy pertensive agents of the following drug classes: 
angiotensin converting enzy me inhibitors (ACE
-inhibitors), angiotensin receptor 
blockers (ARBs), calcium channel blockers, and diuretics (chlorthalidone or a 
thiazide diuretic. L oop diuretics and beta -blockers are NOT pe rmitted). 
b.Non-proliferative diabetic retinopath y, if subject is under the regular care of an 
ophthalmologist and is up-to-date and compliant with the prescribed ongoing 
evaluation and management. Subjects with other diagnosed complications of 
diabetes, such as periphera l neuropathy  and microalbuminuria, may also be 
included.
c.Subjects without history  of myocardial infarction (MI) but who are on aspirin 
may be enrolled.  Subjects with a history  of MI or atherosclerosis are not 
eligible.
d.Other conditions, such as gastroesophageal reflux disease, obstructive sleep 
apnea, osteoarthritis, psoriasis, mood disorders and other chronic stable 
conditions may  be allowed, at the discretion of the Investigator and Sponsor.
4. H ave a diagnosis of T1DM as defined by standa rd diagnostic criteria for ≥12 months 
at time of screening.
5.
Have a serum C-peptide concentration ≤0.7 ng/mL  (0.23 nM) with a concurrent 
plasma glucose >90 mg/dL  (5 mM).  
  04M9RT 
  04W8J9
Product:   MK -5160 23
Protocol/Amendment No.: 002-00 
MK-5160-002-00 Final Protocol 27-Feb-2017
Confidential6.
Be on stable doses of basal insulin over the 2 -week period prior to screening and over
the 2 weeks prior to dosing. Stability  is defined as within approximately  ±20% 
difference in total dail y insulin doses. I nsulin pump users will be allowed.
7. H ave a total daily  insulin requirement (basal plus prandial) of ≤ 1.2 units/kg.
8. H ave a HbA1c ≤10% a t the screening visit.
9.Have a Body Mass Index (BMI ) ≥18.5 kg/m2 and ≤ 32kg/m2.  BMI = mass
(kg)/height (m)2
10.Be a non-smoker or smoker who uses no more than 5 cigarettes or equivalent (e.g., e -
cigarettes) per day over the prior 3 month period also may be enrolled (at the 
discretion of the investigator). The subject must agree to follow the smoking 
restrictions defined b y the CRU.
11.Be willing to comply  withthe trial restrictions (see Section 5.7 for a complete 
summary  of trial re strictions).
For Part2(T2DM) :
1.Subjects provide written informed consent/assent for the trial. The subject may also 
provide consent/assent for Future Biomedical Research.  However, the subject may 
participate in the main trial without participating in Fut ure Biomedical Research.
2.Be male, or female of non -childbearing potential between 18 to 65years of age at the 
pre-trial (screening) visit.
A female of non -childbearing potential is defined as: 
a.A female who is postmenopausal without menses for at least 1 year and has a 
follicle stimulating hormone (FSH) value in the postmenopausal range upon 
pretrial (screening) evaluation,
b.A female who is status post hy sterectomy , oophorectomy  or tubal ligation.  
i. NOTE: These procedures must be confirmed with medical records. In 
the absence of documentation, hysterectom y may be confirmed by 
pelvic exam or if necessary  by ultrasound; oophorectom y may be 
confirmed by hormone levels, particularl y FSH in the post-menopausal 
range, but tubal ligation subjects without records should be excluded.  
Information must be captured appropriately  within the site's source 
documents 
  04M9RT 
  04W8J9
Product:   MK -5160 24
Protocol/Amendment No.: 002-00 
MK-5160-002-00 Final Protocol 27-Feb-2017
Confidential3.Be judged to be in good health based on medical history , physical examination, 
vital 
sign measurements, ECG, and laboratory  safety tests (Section 7.1.3.1) performed at 
pretrial (screening) and prior to administration of the initial dose of trial drug . 
Appendix 12.4 provides a table of 12-Lead Electrocardiogram Abnormality  Criteria 
and Appendix 12.5 provides an algorithm for the assessment of out-of-range 
labo
ratory  values. Subjects with the following conditions may  be enrolled:
a.Hypertension treated with lifesty le modification alone or stable doses (no 
change for ≥3 months) of ≤2 antihy pertensive agents of the following drug 
classes: angiotensinconverting enzyme inhibitors (ACE- inhibitors), 
angiotensin receptor blockers (ARBs), calcium channel blockers, and diuretics 
(chlorthalidone or a thiazide diuretic. Loop diuretics and beta-blockers are 
NOT permitted). 
b.Hypercholesterolemia with stable doses of treatment (no change for > 3 
months), including HMG -CoA reductase inhibitors (statins).  Subjects on 
alternative medications for hypercholesterolemia may be allowed, at the 
discretion of the Investigator and the Sp onsor. 
c.Subjects without history  of myocardial infarction (MI) but who are on aspirin 
may be enrolled.  Subjects with a history  of MI or atherosclerosis are not 
eligible.
d.Non-proliferative diabetic retinopath y, if subject is under the regular care of 
an ophthalmologist and is up-to-date and compliant with the prescribed 
ongoing evaluation and management. Subjects with other diagnosed 
complications of diabetes, such as peripheral neuropath y and 
microalbuminuria, may  also be included.
e.Other conditions, such as gastroesophageal reflux disease, obstructive sleep 
apnea, osteoarthritis, psoriasis, mood disorders and other chronic stable 
conditions may  be allowed, at the discretion of the Investigator and Sponsor.
4. H ave a diagnosis of T2DM as defined by standard diagnostic criteria for ≥12 months 
at time of screening.
5.T2DM subjects 
are not required to have been on insulin.  If on insulin, subjects 
should have a total daily  insulin requirement of ≤ 1.2units/kg , and have beenon 
stable doses of basal insulin over the 2-week period prior to screening and over the 2 
weeks prior to dosing. Stability  is defined as within approximately  ±20% difference 
in total daily  insulin doses. 
6.
In addition to the insulin criteria in #5, meet one of the following criteria:
a.Be on no AH
A, or on metformin monotherap y or metformin plus a DPP4 
inhibitor at stable doses for at least 8 weeks prior to screening, with a 
screening Hb A1C ≥7.0 and ≤10.0%.   
  04M9RT 
  04W8J9
Product:   MK-5160 25
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidentialb.Be on either a sulfony lurea (e.g. glyburide) or an alpha -glucosidase inhibitors 
(e.g., acarbose) alone or in combination with metformin at stable doses for at 
least 8 weeks prior to screening with a screening HbA1C ≥7.0 and ≤9.0%.  
Subjects on these medications must be willing to stop the sulfon ylurea or 
alpha -glucosidase inhibitor after screening once they qualify  for study 
participation .   
7.Have a BMI ≥18.5 kg/m2and ≤ 35.0kg/m2BMI = mass (kg)/height (m)2
8.May be onselected standard medications for T2DM , including alpha -glucosidase 
inhibitors (e.g., acarbose), sulfon ylureas (e.g. glyburide), DPP-4 inhibitors, and 
metformin.  Subjects on alpha -glucosidase inhibitors and/or sulfon ylureas must stop 
these medications for at least one week prior to checking into the site and for the 
duration of the trial through the last dose of MK-5160/glargine .  Subjects on 
metformin or DPP-4 inhibitors may continue on their home dose for the duration of 
the trial.  Subjects on SGL T2 inhibitors (gliflozins) , thiazolidinediones or GLP-1 
agonists are excluded.
9.Be a nonsmoker or smoker who uses no greater than 5cigarettes or equivalent (e.g., 
e-cigarettes) dailyover the prior 3 month period. Subjects must agree to follow the 
smoking restrictions defined by the CRU.
10.Be willing tocomply  with the trial restrictions (see Section 5.7 for a complete 
summary  of trial restrictions).
Subject Exclusion Criteria 5.1.3
The subject must be excluded from participating in the trial if the subject:
For Part1(T1DM) :
1.Is under the age of legal consent
2.Is mentally  or legall y incapacitated, has significant emotional problems at the time of 
pretrial (screening) visit or expected during the conduct of the trial or has a history  of 
clinically  significant psychiatric disorder of the last 5years. Subjects who have had 
situational depression may  be enrolled in the trial at the discretion of the investigator.
3.Has a history  of clinically  significant endocrine (excluding diabetes mellitus ), 
gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, 
respiratory , genitourinary  or major neurological (including stroke and chronic 
seizures) abnormalities or diseases.  Subjects with a history  of uncomplicated kidney 
stones, as defined as spontaneous passage and no recurrence in the last 5 years, or 
childhood asthma may be enrolled in the trial at the discretion of the investigator .  
Subjects with specific chronic stable medical conditions, as noted above, may be 
included at the discretion of the Investigator and Sponsor. 
  04M9RT 
  04W8J9
Product:   MK -5160 26
Protocol/Amendment No.: 002-00 
MK-5160-002-00 Final Protocol 27-Feb-2017
Confidential4.Has a history  of cancer (malignancy )  
Exceptions: (1) Subjects with adequately  treated non-melanomatous skin carcinoma 
or carcinoma in situ of the cervix may participate in the trial; (2) Subjects with other 
malignancies which have been successfully  treated ≥10 years prior to the pretrial 
(screening) visit where, in the judgment of both the investigator and treating 
physician, appropriate follow -
up has revealed no evidence of recurrence from the 
time of treatment through the time of the pretrial (screening ) visit (except those 
cancers identified at the beginning of exclusion criterion 4); or, (3) Subjects, who, in 
the opinion of the trial investigator, are highl y unlikely  to sustain a recurrence for the 
duration of the trial.  
5. S
ubject ha s an estimate d creatinin e clearanc e of < 60 mL/min based on the 
Cockcr
oft-Gaul t equation; th e Coc kcroft-Gaul t equation i s (for females multiply  
result by  0.85):
ClCr=(140-age[yr ])(body wt [kg])
(72)(serum creat [mg/dL])
When creatinine is measured in mi cromole/litre, use the following formul a:
ClCr= (14
0-age[ yr])(bo dy wt[kg])
(72)(serum creatinine [mic romol/L] x 0.0113)
6.Has a history  of significant multiple and/or severe allergies (e.g. food, drug, latex 
allergy ), or has had an anaphy lactic reaction or significant intolerability  (i.e. systemic 
allergic reaction) to prescription or non
-prescription drugs or food. 
7.Is positive for hepatitis B surface antigen, hepatitis C antibodies or HIV at Screening.
8.Had major surgery , donated or lost 1 unit of blood (approximately  500 mL) within 4 
weeks prior to the pretrial (screening) visit. 
9.Has participated in another investigati onal trial within 4 weeks (or 5 half-lives), 
whichever is greater, prior to the pretrial (screening) visit.  The window will be 
derived from the date of the last visit in the previous trial.  
10.Has QTc interval >450 msec, has a history  of risk factors for Torsades de Pointes 
(e.g., heart failure/cardiomy opath y or famil y history  of Long QT Syndrome), has 
uncorrected hy pokalemia or hy pomagnesemia, is taking concomitant medications that 
prolong the QT/QTc interval at Screening.
11.Is unable to refrain from or anticipates the use of any medication, including 
prescription and non-prescription drugs or herbal remedies beginning approximately  
2 weeks (or 5 half-lives) prior to administration of the initial dose of trial drug, 
throughout the trial (including washout intervals between treatment periods), until the 
post-trial visit.  Certain medications, such as antihy pertensives and aspirin ,are 
permitted, see Section s5.1.2 and 5.5. 
  04M9RT 
  04W8J9
Product:   MK -5160 27
Protocol/Amendment No.: 002-00 
MK-5160-002-00 Final Protocol 27-Feb-2017
Confidential12.Consumes greater than 3glasses of alcoholic beverages (1 glass is approximately  
equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spirits 
[29.5 mL/1 ounce]) per day.  Patients that consume 4 glasses of alcoholic beverages 
per day  may  be enrolled at the discretion of the investigator.
13.Consumes excessive amoun
ts, defined as greater than 6 servings 
(1 serving is approximately  equivalent to 120 mg of caffeine) of coffee, tea, cola, 
energy -drinks, or other caffeinated beverages per day .
14.Is a regular user of cannabis orany illicit drugs ,or has a history  of drug (including 
alcohol) abuse within approximately  6 m onths. Subjects must have a negative UDS 
prior to randomization.  
15.Is an y concern by  the investigator regarding the safe participation of the subject in the 
trial or for any other reason the investigator considers the subject inappropriate for 
participation in the trial
16.Has a history  of diabetic ketoacidosis in the last 12 months.
17.Has the diagnosis of hypogl ycemia unawareness, or has had one or more severe 
hypoglycemic episodes associated with hypogl ycemic seizures, comas or 
unconsciousness within 6 months prior to dosing.
18.Has used systemic (intravenous, oral, inhaled) glucocorticoids within 3 months of 
screening or is anticipated to require treatment with systemic glucocorticoids during 
study  participation.
19.Has other major medical problems requiring medication (i.e
.,history  of MI, 
hypercholesterolemia).  Subjects on aspirin as prophy laxis may be enrolled, provided 
there is no history  of MI or other thromboembolic event, or a history  of coronary 
atherosclerosis.   As noted above, subjects with other medical problems (i.e., 
gastroesophageal reflux disease) may be included in the trial at the discretion of the 
Investigator and Sponsor.
20.Has a known history  of celiac disease or significant food allergy , at the discretion of 
the Investigator and Sponsor.
21.Has a history  of hypersensitivity  to pharmacologic insulins or to any of the inactive 
ingredients in regular human insulin, or to any  E.coli -derived drug product.
22.Is or has an immediate family  member (e.g., spouse, parent/legal guardian, sibling or 
child) who is investigational site or Sponsor staff directly  involved with this trial.
For Part2(T2DM) :
1.
Is under the age of legal consent
2.Is mentally  or legall y incapacitated, has significant emotional problems at the time of 
pretrial (screening) visit or expected during the conduct of the trial or has a history  of 
clinically  significant psychiatric disorder of the last 5 years. Subjects who have had 
situational depression may  be enrolled in the trial at the discretion of the investigator. 
  04M9RT 
  04W8J9
Product:   MK -5160 28
Protocol/Amendment No.: 002-00 
MK-5160-002-00 Final Protocol 27-Feb-2017
Confidential3.Has a history  of clinically  significant endocrine (excluding diabetes mellitus) , 
gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, 
respiratory , genitourinary  or major neurological (including stroke and chronic 
seizures) abnormalities or diseases.  Subjects with a history  of uncomplicated kidney 
stones, as defined as spontaneous passage and no recurrence in the last 5 years, or 
childhood asthma may be enrolled in the trial at the discretion of the investig ator.  
Subjects with specific chronic stable medical conditions, as noted above, may be 
included at the discretion of the Investigator and Sponsor.
4.Has a history  of cancer (malignancy )  
Exceptions: (1) Subjects with adequately  treated non-melanomatous skin carcinoma 
or carcinoma in situ of the cervix may participate in the trial; (2) Subjects with other 
malignancies which have been successfully  treated ≥10 years prior to the pretrial 
(screening) visit where, in the judgment of both the investigator and treating 
physician, appropriate follow -
up has revealed no evidence of recurrence from the 
time of treatment through the time of the pretrial (screening) visit (except those 
cancers identified at the beginning of exclusion criterion 4); or, (3) Subjects, who, in 
the opinion of the trial investigator, are highl y unlikely  to sustain a recurrence for the 
duration of the trial.  
5. S
ubject ha s an estimate d creatinin e clearan ce of <60mL/min based on the 
Cockcr
oft-Gaul t equation; th e Cockcroft-Gaul t equation i s (for females multiply  
result by  0.85):
ClCr=(140-a
ge[yr ])(body wt [kg])
(72)(serum creat [mg /dL])
When creatinine is measured in mi cromole/litre, use the following formul a:
ClCr= (14
0-age[ yr])(bo dy wt[kg])
(72)(serum creatinine [mic romol/L] x 0.0113)
6.Has a history  of significant multiple and/or severe allergies (e.g. food, drug, latex 
allergy ), or has had an anaphy lactic reaction or significant intolerability  (i.e. systemic 
allergic reaction) to prescription or non
-prescription drugs or food. 
7.Is posit ive for hepatitis B surface antigen, hepatitis C antibodies or HIV at Screening.
8.Had major surgery , donated or lost 1 unit of blood (approximately  500 mL) within 4 
weeks prior to the pretrial (screening) visit. 
9.Has participated in another investigational trial within 4 weeks (or 5 half-lives), 
whichever is greater, prior to the pretrial (screening) visit.  The window will be 
derived from the date of the last visit in the previous trial.  
10.Has QTc interval >450 msec, has a history  of risk factors for Torsad es de Pointes 
(e.g., heart failure/cardiomy opath y or famil y history  of Long QT Syndrome), has 
uncorrected hy pokalemia or hy pomagnesemia, is taking concomitant medications that 
prolong the QT/QTc interval at Screening. 
  04M9RT 
  04W8J9
Product:   MK -5160 29
Protocol/Amendment No.: 002-00 
MK-5160-002-00 Final Protocol 27-Feb-2017
Confidential11.Is unable to refrain from or anticipat es the use of any medication, including 
prescription and non
-prescription drugs or herbal remedies beginning approximately  
2 weeks (or 5 half-lives) prior to administration of the initial dose of trial drug, 
throughout the trial (including washout interval s between treatment periods), until the 
post-trial visit.  Certain medications are permitted, including antihy pertensives, 
aspirin, and HMG -CoA reductase inhibitors ( see Section s 5.1.2 and 5.5).
12.Consumes greater than 3glasses of alcoholic beverages (1 glass is approximately  
equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spirits 
[29.5 mL/1 ounce]) per day.  Patients that consume 4 glasses of alcoholic beverages 
per day  may  be enrolled at the discretion of the investigator.
13.Consumes excessive amounts, defined as greater than 6 servings 
(1 serving is approximately  equivalent to 120 mg of caffeine) of coffee, tea, cola, 
energy -drinks, or other caffeinated beverages per day .
14.Is a regular user of cannabis orany illicit drugs , o
r has a history  of drug (including 
alcohol) abuse within approximately  6 m onths. Subjects must have a negative UDS 
prior to randomization.
15.Is an y concern by  the investigator regarding the safe participation of the subject in the 
trial or for any other reason the investigator considers the subject inappropriate for 
participation in the trial
16. H as other major medical problems requiring medication (i.e
.,history  of MI, 
hypercholesterolemia ). Subjects on aspirin as prophy laxis may be enrolled, provided 
there isno history  of MI or other thromboembolic event, or a history  of coronary 
atherosclerosis.  As noted above, subjects with other medical problems (i.e., 
gastroesophageal reflux disease) may be included in the trial at the discretion of the 
Investigator and Sponsor. 
17.Has the diagnosis of hypogl ycemia unawareness, or has had one or more severe 
hypoglycemic episodes associated with hypogl ycemic seizures, comas or 
unconsciousness within 6 months prior to dosing.
18.Has a known history  of celiac disease or significa nt food allergy , at the discretion of 
the Investigator and Sponsor.
19. H as used systemic (intravenous, oral, inhaled) glucocorticoids within 3 months of 
screening or is anticipated to require treatment with systemic glucocorticoids during 
study  participation.
20.Has been treated with an SGL T2 inhibitor (gliflozins), thiazolidinedione
or GLP-1 
receptor agonist
within the past three months .
21. H as a history  of hypersensitivity  to pharmacologic insulins or to any of the inactive 
ingredients in regular human insulin, o r to any  E.coli -derived drug product.
22.Is or has an immediate family  member (e.g., spouse ,parent/ legal guardian, sibling or 
child) who is investigational site or S ponsor staff directly involved with this trial. 
  04M9RT 
  04W8J9
Product:   MK-5160 30
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialTrial Treatment(s) 5.2
The t reatment (s)to be used i n this trial are outlined below in Table 3.
Table 3Trial Treatment
Drug, 
Vaccine, 
Biologic, 
Device, etc.Dose/PotencyDose 
FrequencyRoute of 
AdministrationRegimen/Treatment 
Period RegimenUse
MK-5160 Potency: 
20 mg/mLDaily for 
12daysSubcutaneous Parts 1 & 2 all 
panelsExperimental 
Glargine 100 U/mL Daily for 
12daysSubcutaneous Parts 1 & 2 all 
panelsActive 
comparator
Dextrose 20% solution; 
adjusted to 
maintain the 
various 
glycemic 
levels at 100 
mg/dLContinuous 
infusion for 
6-30 hours 
(as needed 
to maintain 
blood sugar 
at 100 
mg/dLIntravenous Parts 1 & 2 all 
panelsGlucose 
Clamp 
Assessment
Placebo Not 
applicableDaily for 
12daysSubcutaneous Parts 1 & 2 all 
panelsComparator
Trial treatment should begin on the day of treatment allocation/ randomization or as close as 
possible to the date on which the subject is allocated/assigned.
All supplies indicated in Table 3above will be provided centrall y by the Sponsor or locally  
by the trial site, subsidiary or designee, depending on local country  operational or regulatory 
requirements.
For any commercially  available product that is provided by the trial site, subsidiary  or 
designee every  attempt will be made to source these supplies from a single lot/batch number. 
The trial site is responsible for recording the lot number, manufacturer, and expiry  date for 
any locally  purchased product as per local guidelines unless other wise instructed by the 
Sponsor .
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate suppl y, storage, handling, distribution and usage of trial 
treatments in accordance with the prot ocol and an y applicable laws and regulations. 
  04M9RT 
  04W8J9
Product:   MK-5160 31
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialDose Selection/Modification 5.2.1
Dose Selection (Preparation) 5.2.1.1
The rationale for selection of doses to be used in this trial is provided in Section 4.0 –
Background & Rationale.  Specific calculations or evaluations required to be performed in 
order to administer the proper dose to each subject are outlined ina separate document 
provided b y the Sponsor.
Dose Modification (Escalation/Titration/Other) 5.2.1.2
Dose escalation decisions will be based on key  safety  variables including, vital signs, 12 -lead 
ECG, laboratory  safety tests, and adverse events  from the previous dose levels up to at least 
24 hours (or longer depending on the compound). Pharmacokinetic and pharmacod ynamic 
data may be included in the dose escalation decisions.  See Background & Rationale -
Section 4.0 .
If, as judged by the Sponsor and investigator, the safet y and tolerability  data do not justify 
dose escalation, the dose wil l not be increa sed as planned. Instead, subjects may :
● receive the same dose level to further explore safety and tolerability at that level;
● receive a lower dose of the trial drug;
● receive the same or lower dose as a divided dose; or
● receive a lower dose with or w ithout food.
Or, dosing may  be stopped. Subject discontinuation criteria are outlined in Section 5.8.
Prior to each treatment, the clinical and laboratory  safety parameters from the previous dose 
level will be reviewed by the investigator and discussed with the Sponsor to permit a 
decision on whether to advance to the next higher dose level.  No dose escalation will occur 
without the joint agreement of the investigator and the Sponsor .
Timing of Dose Administration 5.2.2
MK- 5160 or glargine will be prepared and d osed in the morning following a fast of at least 8 
hours per the instructions outlined in the Study  Operations Manual.
Trial Blinding 5.2.3
A double -blinding technique will be used.  MK-5160 and glargine will be prepared and/or 
dispensed in a blinded fashion byan unblinded pharmacist or qualified trial site personnel . 
The subject andthe investigator who isinvolved in the treatment or clinical evaluation of the 
subjects are unaware of the group assignments.
Subjects will be administered placebo ,as well as MK-5160 or glargine, so that subjects 
receive two injections –MK- 5160 and glargine -matched placebo, or glargine and MK-5160 -
matched placebo.
See Section 7.1.4.2, Blinding/Unblinding, for a description of the method of unblinding a 
subject during the trial, s hould such action be warranted. 
  04M9RT 
  04W8J9
Product:   MK-5160 32
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialRandomization or Treatment Allocation 5.3
Subjects will be assigned randomly  according to a computer -generated allocation schedule. 
See sample in Table 4.
Table 4Sample Allocation Schedule 
Part 1 (T1DM Patients)
Subjects Panel A Panel B Panel C
N=6
N=2MK-5160 16 nmol/kg SC
Glargine 0.4 U/kg
N=6
N=2MK-5160 32 nmol/kg SC
Glargine 0.4 U/kg
N=6
N=2MK-5160 ≤64nmol/kg SC
Glargine 0.4 U/kg
Part 2 (T2DM Patients)
Subjects Panel D Panel E Panel F
N=6
N=2MK-5160 16 nmol/kg SC
Glargine 0.6 U/kg
N=6
N=2MK-5160 32 nmol/kg SC
Glargine 0.6 U/kg
N=6
N=2MK-5160 ≤64nmol/kg SC
Glargine 0.6 U/kg
Subjects will participate in only one panel  
To maintain blinding, subjects will receive two injections at each administration –one active (MK -5160 or glargine) and 
one placebo due to potential differing volumes of the active treatments. 
Stratification 5.4
No stratification based on age, sex or other characteristics will be used in this trial.
Concomitant Medications /Vaccinations (Allowed & Prohibited) 5.5
Medications or vaccinations specifically  prohibited in the exclusion criteria are not allowed 
during the ongoing trial.  If there is a clinical indication for any medication or vaccination
specificall y prohibited during the trial, discontinuation from trial therapy or vaccination may 
be required.  The investigator should discuss any questions regarding this with the Sponsor .  
The final decision on any  supportive therapy  or vaccination rests with the investigator and/or 
the subject's primary  physician.  However, the decision to contin ue the subject on trial 
therap y or vaccination schedule requires the mutual agreement of the investigator, the 
Sponsor and the subject.
Ibuprofen may  be used for minor ailments without prior consultation with the Sponsor, and is 
permissible to have been ta ken prior to the trial.
Listed below are specific restrictions for concomitant therap y during the course of the trial:
1.Subjects on asulfony lurea or alpha -glucosidase inhibitors may be included in the 
trial, provided these medications are stopped at least one week prior to checking into 
the site .  
2. Subjects on metformin and/or DPP -4 inhibitor mustcontinue their home dose for the 
duration of the trial. 
  04M9RT 
  04W8J9
Product:   MK-5160 33
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidential3.SGL T2 inhibitors (gliflozins ), thiazolidinediones and GLP -1 agonists are not allowed.  
Subjects who have taken these medications within three months of screening are 
excluded from the trial.
4.Subject s with a diagnosis of hypercholesterolemia are excluded from Part 1. Lipid-
lowering medications (HMG -CoA reductase inhibitors) would ,therefore ,not be 
allowed in subjects in Part 1.  Subjects in Part 2 (T2DM) may remain on lipid -
lowering medications.
5.Subjects on aspirin for thrombosis prophy laxis, without history  of MI, other 
thromboemboli c event or atherosclerosis requiring procedural intervention , may 
remain on aspirin for the duration of the trial.
6.Beta-blockers and loop diuretics are not allowed.  Subjects on these medications will 
be excluded.
7.Systemic glucocorticoids are not allowed. Subjects on inhaled or topical 
glucocorticoids may  be allowed, at the discretion of the Investigator and Sponsor.
8.Other concomitant medications not addressed above (i.e., proton pump inhibitors, 
anti-depressants) may be allowed, at the discretion of the Investigator and Sponsor.
Rescue Medications & Supportive Care 5.6
To ensure subject safety , this study  is conducted at an experienced Phase I clinical research 
unit with ACL S-trained medical staff available to intervene in case of severe hypogly cemia 
or diabetic ketoacidosis . Resuscitative equipment and rescue treatment will be available at 
theclinical research unit during the trial. In addition, the clinical research unit has immediate 
access to a full service acute -care hospital to facilitate rapid institution of medical 
intervention ifrequired. Refer to Appendix 12.6for additional details on intervention for
hypo-and h ypergl ycemia .
Diet/Activity/Other Considerations 5.7
Diet 5.7.1
On clamp days , i.e. Days 1and 12, subjects will fast from all food and drinks, except water, 
for at least 8hours prior to trial drug administration /clamp procedure .  Subjects will remain 
fastedfrom all food and drinks except water until approximately  1 hour after the end of the 
clamp procedure .  Standardized, uniform meals and snack(s) will be provided by the 
investigator in accordance with the site’s standard schedule .  Subjects will fast from all food 
and drinks except water between meals and snacks. The caloric content and composition of 
meals will be the same on each full pharmacokinetic sampling day  in each panel. 
On intermediate days (Days 2-11), subjects will fa st from all food and drinks, except water, 
for at least 8hours prior to trial drug administration.  Subjects may eat after dosing on non -
clamp days.  Meals and snacks will be standardized with respect tocaloric content, 
composition and timing.   On Day 7,all subjects will fast after the afternoon snack (i.e. there 
will be no dinner or evening snack).  Subjects will remain fasted overnight until after the 
morning blood draw and dosing.  On Day 9, subjects who tolerated the fasting on Day 7 (at 
the discreti on of the Investigator) will undergo similar fasting after the afternoon snack, with  
  04M9RT 
  04W8J9
Product:   MK-5160 34
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidentialno dinner or evening snack. Subjects may consume water during this time, and will be 
monitored for h ypoglycemia.
Alcohol, Caffeine, Tobacco, Activity 5.7.2
Alcohol Restrictions 5.7.2.1
Subjects will refrain from consumption of alcohol 24 hours prior to the pre-and post-trial 
visits ,from 24 hours prior to trial drug administration ,while domiciled in the clinical unit . At 
all other times (between screening and domiciling , and between Days 15-19), alcohol 
consumption is limited to no more than approximately  3 alcoholic beverages or equivalent (1 
glass is approximately  equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or 
distilled spirits [29.5 mL /1 ounce]) per day .
Caffein e Restrictions 5.7.2.2
Subjects will refrain from consumption of caffeinated beverages or xanthine -containing 
products from 12 hours prior to the pre-and post-trial visits. Subjects will refrain from 
consumption of caffeinated beverages or xanthine -containing products while domiciled and 
during the days immediately  afterward (Day s 15-19).  
Smoking Restrictions 5.7.2.3
Smoking (and/or the use of nicotine/nicotine -containing products) is not permitted during the 
trial.
Activity Restrictions 5.7.2.4
Subjects will avoid unaccustomed strenuous physical activity  (i.e., weight lifting, running, 
bicycling, etc.) from the pre-trial (screening) visit until administration of the initial dose of 
trial drug, and until the post-trial visit.   During the domiciling period, subjects will engage in 
activity  as per site specifications.
Contraception 5.7.2.5
Male subjects with female partner(s) of child -bearing potential must agree to use a medically 
acceptable method of contraception during the trial and for 90 days after the last dose of trial
drug. Males should use a condom. Female partners must additionally use one of the 
following methods if they are not pregnant: hormonal contraception, intra -uterine device, 
diaphragm, or cervical cap. If their partner is pregnant, males must agree to use acondom 
and no additional method of contraception is required for the pregnant partner. Male subjects 
must also agree to no tdonate sperm during the study  and for a period of 90 day s after the last 
dose of study  drug.
Subject Withdrawal/Discontinuation Cri teria 5.8
Discontinuation of Treatment 5.8.1
Discontinuation of treatment does not represent withdrawal from the trial. 
  04M9RT 
  04W8J9
Product:   MK-5160 35
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialAs certain data on clinical events beyond treatment discontinuation may be important to the 
study , they must be collected through the subject’s last scheduled follow -up, even if the 
subject has discontinued treatment .  Therefore, all subjects who discontinue trial treatment
prior to completion of the treatment period will still continue to participate in the trial as 
specified in Section 6.0 -Trial Flow Chart and Section 7.1.4.1 –
Withdrawal/Discontinuation, or if available, Protocol Clarification Letter.
Subjects may discontinue treatment at any time for any reason or be dropped from treatment
at the discretion of the investigator should any untoward effect occur.  In addition, a subject 
may be discontinued from treatment by the investigator or the Sponsor if treatment is 
inappropriate, the trial plan is violated, or for administrative and/or other safety  reasons.  
Specific details regarding procedures to be performed at treatment discontinuation are 
provided in Section 7.1.4 –Other Procedures.
A subject must be discontinued from treatment ,but continue to be monitored in the trial for 
any of the following reasons:
oThe subject or subject’s legally acceptable representative requests to discontinue 
treatment .
oThe subject’s treatment assignment has been unblinded by the investigator, Merck 
subsidiary  or through the emergency  unblinding call center. 
oThe subject interrupts trial medication administrati on for more than 1 consecutive day
or has 2cumulative missed doses.
oThe subject has a medical condition or personal circumstance which, in the opinion of 
the investigator and/or Sponsor , placed the subject at unnecessary  risk from continued 
administration of study  drug/vaccine .
oThe subject has a positive urine drug screen at any time during the course of the trial.
oThe subject has liver function test (ALT and/or AST) value changes of  ≥3 times the 
upper limit of normal that are not associated with any plausible cause. May consider 
discontinuation of study .
oThe subject has QTcF prolongation meeting pre-specified criteria (see Appendix 
12.4).
For subjects who are discontinued from treatment, all applicable discontinuation activities 
will be performed accordin g to Section 7.1.4. 1 –Withdrawal/Discontinuation , or if available, 
Protocol Clarification Letter.
Discontinuation from treatment is “permanent.” Once a subject is discontinued, he/she shall 
not be allowed to restart treatment .
Withdrawal from the Trial 5.8.2
Subjects may withdraw from the trialat any  time for any  reason.  If a subject withdraws from 
the trial, they  will no longer receive treatment or be followed at scheduled protocol visits. 
  04M9RT 
  04W8J9
Product:   MK-5160 36
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialA subject must be withdrawn from the trialif:
oThe subject or subject ’s legally  acceptable representative withdraws consent from the 
study .
oThe subject is lost to follow -up.
Specific details regarding procedures to be performed at the time of withdrawal from the trial 
including the procedures to be performed should asubject repeatedl y fail to return for 
scheduled visits and/or if the study  site is unable to contact the subject, as well as specific 
details regarding withdrawal from Future Biomedical Research are outlined in Section 7.1.4 
–Other Procedures.
Subject Re placement Strategy 5.9
If a subject discontinues from trial treatment or withdraws from the trial, a replacement 
subject may be enrolled if deemed appropriate by the investigator and Sponsor.  The 
replacement subject will generall y receive the same treatment or treatment sequence (as 
appropriate) as the subject being replaced. The replacement subject will be assigned a unique 
treatment/randomization number. The trial site should contact the Sponsor for the 
replacement subject’s treatment/ randomization number.
Beginning and End of the Trial 5.10
The overall trial begins when the first subject signs the informed consent form.  The overall 
trial ends when the last subject completes the last study-related phone -call or visit, withdraws 
from the trial or is lost to follow -up (i.e. the subject is unable to be contacted by the 
investigator).
A trial may be paused during review of newly  available preclinical/clinical safet y, 
pharmacokinetic, pharmacody namic, efficacy  or biologic data or other items of interest, prior 
to a final decision on continuation or termination of the trial.  It may  be necessary  to keep the 
trial open for gathering/reviewing of additional supportive data to optimally  complete the 
objective(s) of the trial.  If necessary , the appropriate amendment(s) to the protocol and/or 
appropriate communication(s) will be generated.  The overall trial end will then not be 
identified until the Sponsor has made the decision to end the trial following this review 
period.  The Competent Authority (ies) and Institutional Review Board(s)/Independent Ethics 
Committee(s) [I RB(s)/IEC(s)] will be appraised of the maximum duration of the trial bey ond 
the last subject out and the justification for keeping the trial open.
Clinical Criteria for Early Trial Termination 5.11
There are no pre -specified criteria for terminating the trial earl y. 
  04M9RT 
  04W8J9
 
  04W8J9
 
  04W8J9
Product:   MK -5160 39
Protocol/Amendment No.: 002-00 
MK-5160-002- 00 Final Protocol 27-Feb-2017
Confidentiala
. All subjects will participate in only 1 Panel .
b. Screening should be done within 30days of Day 1.
c. Weight will be obtained with the subjects shoes off, jacket or coat removed, with a single calibrated scale. Weight obtained at baseline (Day -1) will be used for determining 
amount of drug to be administered.
d. All ECGs will be obtained in triplicate at least 1 -2 m inutes apart daily around the same time on non -clamp days (predose) .  On Day -1, ECGs will be obtained. The mean of 
these measurements will be used as the baseline. During the clamp procedure (see Clamp Flow Chart ) ECG measurements will be taken in triplicate atpredose, 60 min (1.0 
hr), 180min ( 3.0 hr), 360 min (6.0 hr), 9.0 hr, 12.0 hr, 18.0 hr, 24.0 hr, 30.0 hr and 36.0 hr. Measurements will also be collected at Post clamp.
e. At screening, the mean of 3 measurements taken within a 10 -minute period (all 3 sets completed within 10 minutes) will be used to assess for subject eligibility. This may be 
repeated on a second screening day at the discretion of the study investigator. On Day 1, HR and BP will be triplicate measurements obtained at least 1-2 minutes apart 
within approximately 60 minutes prior todosing MK-5160/glargine . Themean of these measurements will be used as the baseline. On the day of clamp procedures , post-
dose Vi tal Sign assessments will be done at 30 min (0.5h), 60 min (1h), 180min ( 3.0 hr), 360 min (6 hr), 9.0 hr, 12.0 hr, 18.0 hr, 24.0 hr, 30 hr, and 36 hr. 
f. Injection site local tolerability assessment will be recorded as an AE if any reactions are identifi ed.
g. A dverse experiences (including serious adverse events) will be reported from the signing of informed consent through 33days (5 days from Day 28) following cessation of 
treatment . 
h. For postmenopausal females without menses for at least 1 year.
i. Screening UDS is mandatory, any additional UDS are conducted per site SOP
j. This sample should be drawn for planned analysis of the association between genetic variants in DNA and drug response.   This sample will not be collected at the site if 
there is either a local law or regulation prohibiting collection, or if the IRB/IEC does not approve the collection of the sample for these purposes. If the sample is collected, 
leftover extracted DNA will be stored for future biomedical research if the subject signs the FBR consent. If the planned genetic analysis isnot approved, but FBR is 
approved and consent is given, this sample will be collected for the purpose of FBR.
k. Leftover main study plasma will be stored for future biomedical research if the subje ct consents to future biomedical research . 
l. Blood for Plasma MK-5160 Assay will be collected daily and at the following timepoints on the Day 1 clamp : -15 min (predose), 10, 30, 60, 90, 120, 180, 240, 360, 480, 
600, 720, and 1440 minutes following start of injection (i.e. -15 min, 10min, 30min, 1h, 1.5 h, 2h, 3h, 4h, 6h, 8h, 10h, 12h ,and 24 h, after s.c. dose). For the second clamp on 
Day 12, the following timepoints will be collected : -15 min (predose), 10, 30, 60, 90, 120, 180, 240, 360, 480, 600 , 720, 1440 minutes (24h, Day 13), 48h (Day 14), 72h (Day 
15), 96h (Day 16), 120h (Day 17) and 168h (Day 19) following start of injection. Blood will also be collected at Post-trial (28 days). Exploratory analysis for MK-5160 
metabolites may be performed. 
m. Refer to the Study Operations Manual for clamp procedures including how to initiate and titrate glucose infusion levels to target and maintain plasma glucose at 100 mg/dL . 
Glucose infusion will be discontinued at the discretion of the investigator as detailed in the Study Operations Manual. The duration of the infusion may be shorter or longer 
than specified .
n. On these days, subjects will only be fed these meals: Day 7 –breakfast and lunch; Day 9 – breakfast and lunch.
o. Plasma for bedside glucose analysis should be collected at approximately -5 min predose and every 1 to 10 minutes. If necessary, collection may be performed more 
frequently at the investigator’s discretion.
p. Fingersticks should occur before meals ,before bedtime (~11:00 PM) , and as needed overnight .
q. Subjects are discharged on Day 14, but return to the CRU on Day 15, Day 16, Day 17 and Day 19 for PK draws.
r. Subjects may elect to stay in the unit through Day 19 if the Investigator and the subj ect feel there is a risk in being unable to return for the PK visits from Days 15 -19.
s. For T1DM subjects only. 
  04M9RT 
  04W8J9
 
  04W8J9
Product:   MK-5160 41
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidential7.0TRIAL PROCEDURES
Trial Procedures 7.1
The Trial Flow Chart -Section 6.0summarizes the trial procedures to be performed at each 
visit.  Individual trial procedures are described in detail below.  It may be necessary  to 
perform these procedures at unscheduled time points if deemed clinically necessary  by the 
investigator.
Furthermore, additional evaluations/testing may  be deemed necessary  by the investigator and 
or the Sponsor for reasons related to subject safety . In some cases, such evaluation/testing 
may be potentially  sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus local regulations 
may require that additional informed consent be obtained from the subject.  In these cases, 
such evaluations/testing will be performed in accordance with those regulations.
Administrative Procedures 7.1.1
Informed Consent 7.1.1.1
The investigator or qualified designee must obtain documented consent from each potential 
subject or each subject’s legally  acceptable representative prior to participating in a clinical 
trial or Future Biomedical Research .If there are changes to the subject’s status during the 
trial (e.g. ,health or age of majority  requirements ), the investigator or qualified designee must 
ensure the ap propriate consent is in place. 
7.1.1.1.1 General Informed Consent
Consent must be documented by the subject’s dated signature or by the subject’s legally 
acceptable representative’s dated signature on a consent form along with the dated signature 
of the person conducting the consent discussion. 
A copy  of the signed and dated consent form should be given to the subject before 
participation in the tri al.
The initial informed consent form, any subsequent revised written informed consent form 
and any written information provided to the subject must receive the IRB/ERC’s 
approval/favorable opinion in advance of use.  The subject or his/her legally  accepta ble 
representative should be informed in a timel y manner if new information becomes available 
that may be relevant to the subject’s willingness to continue participation in the trial.  The 
communication of this information will be provided and documented via a revised consent 
form or addendum to the original consent form that captures the subject’s dated signature or 
by the subject’s legall y acceptable representative’s dated signature.
Specifics about a trial and the trial population will be added to the consent form template at 
the protocol level.  
The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations 
and Sponsor requirements. 
  04M9RT 
  04W8J9
Product:   MK-5160 42
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidential7.1.1.1.2 Consent and Collection of Specimens for Future Biomedical Research
The investigator or qualified designee will explain the Future Biomedical Research consent 
to the subject, answer all of his/her questions, and obtain written informed consent before 
performing an y procedure related to the Future Biomedical Research sub -trial.  A copy  of the 
informed consent will be given to the subject.
Inclusion/Exclusion Criteria 7.1.1.2
All inclusion and exclusion criteria will be reviewed by  the investigator or qualified designee 
to ensure that the subject qualifies for the trial.
Subject Identification Card 7.1.1.3
All subjects will be given a Subject Identification Card identify ing them as participants in a 
research trial. The card will contain trial site contact information (including direct telephone 
numbers) to be utilized in the event of an emergency . The investigat or or qualified designee 
will provide the subject with a Subject Identification Card immediately  after the subject 
provides written informed consent. At the time of treatment allocation/randomization, site 
personnel will add the treatment/randomization num ber to the Subject Identification Card.
The subject identification card also contains contact information for the emergency  
unblinding call center so that a health care provider can obtain information about trial 
medication/vaccination in emergency  situati ons where the investigator is not available.
Medical History 7.1.1.4
A medical history  will be obtained by  the investigator or qualified designee.
Prior and Concomitant Medications Review 7.1.1.5
7.1.1.5.1 Prior Medications
The investigator or qualified designee will review prior medication use, including any 
protocol -specified washout requirement, and record prior medication taken by the subject 
within 14days before starting the trial.
7.1.1.5.2 Concomitant Medications
The investigator or qualified designee will record medication, if any, taken by the subject 
during the trial.
Assignment of Screening Number 7.1.1.6
All consented subjects will be given a unique screening number that will be used to identify 
the subject for all procedures that occur prior to randomization or treatment allocation .  Each 
subject will be assigned only one screening number.  Screening numbers must not be re -used 
for different subjects.
Any subject who is screened multiple times will retain the original screening number 
assigned at the initial screening visit. 
  04M9RT 
  04W8J9
Product:   MK-5160 43
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialSpecific d etails on the screening visit requirements (screening/rescreening) are provided in 
Section 7.1.5.1.  
Assignment of Treatment/ Randomization Number 7.1.1.7
All eligible subjects will be randoml y allocated and will receive a treatment/ randomization 
number.  The treatment/ randomization number identifies the subject for all procedures 
occurring after randomization.  Once a treatment/ randomization number is assigned to a 
subject, it can never be re -assigned to another subject.
A single subject cannot be assigned more th an 1 treatment/ randomization number.
Trial Compliance (Medication/Diet/Activity/Other) 7.1.1.8
Administration of trial medication will be witnessed by  the investigator and/or trial staff.
Clinical Procedures/Assessments 7.1.2
Physical Exam:
The phy sical exam assessments will be defined and conducted per the site SOP.
Body Weight and Height
Body weight and height will be obtained with the subjects shoes off, jacket or coat removed
with a single calibrated scale .
Body Mass Index (BMI)
BMI equals a person's weight in kilogr ams divided by height in meters squared. 
(BMI=kg/m2).  Document this BMI to the nearest 0.1 kilogram/(meter)2.  
Weigh the subject’s after an overnight fast, after voiding, while in a gown or underwear, 
without shoes, on a calibrated scale.  Document this weight in kilograms (kg), to the nearest 
0.1 kg.  
Measure the subject’s height on a calibrated stadiometer, without shoes.  Document this 
height in meters, to the nearest 0.01 meter (0.01 meter = 1 centimeter, cm).  
12-Lead ECG
Special care must be taken for proper lead placement by qualified personnel. Skin should be 
clean and dry prior to lead placement.  Subjects may need to be shaved to ensure proper lead 
placement.  Female subjects may need to remove their bra.  
Subjects should be resting in the semi-recumbent for at least 10 minutes prior to each ECG 
measurement.  
The correction formula to be used for QTc is Fredericia.
If repeat ECGs are required the clinical site will decide whether to leave the electrodes in 
place or mark the position of the electrodes for subsequent ECGs.  To mark the position of 
the electrodes, 12-lead electrode sites will be marked on the skin of each subject with an 
ECG skin marker pen to ensure reproducible electrode placement. 
  04M9RT 
  04W8J9
Product:   MK -5160 44
Protocol/Amendment No.: 002-00 
MK-5160-002- 00 Final Protocol 27-Feb-2017
ConfidentialPredose ECGs will be obtained in triplicate at least 1-
2 minutes apart within 1-2 hours prior 
to dosing MK-5160.  The mean of these measurements will be used as the baseline to 
calculate change from baseline for safet y evaluations (and for rechecks, if needed).  
During each treatment period, if a subj ect demonstrates an increase in QTc interval ≥60 msec 
compared with mean predose baseline measurement, the ECG will be repeated twice within 5 
minutes.  The mean value of the QTc interval from the 3 ECGs will represent the value at 
that time point.  If the mean  QTc interval increase from baseline for any postdose time point 
is ≥60 msec, the subject will continue to be monitored by repeat 12-lead ECGs every  15 
minutes for at least 1 hour or until the QTc is within 60 msec of baseline.  If prolongation of 
the QTc interval ≥60 msec persists, a consultation with a study  cardiologist may be 
appropriate and the Sponsor should be notified.
If the QTc interval is 500 msec, the Sponsor should be notified and the ECGs should be 
reviewed b y a cardiologist. The subje ct should be telemetry -monitored (until the QTc is <500 
msec) or should be considered for transfer to a location where closer monitoring and 
definitive care (e.g., a Cardiac or Intensive Care Unit) is available.
Monitoring of potassium levels at the bedsid
e will be performed as deemed necessary  at the 
discretion of the investigator. 
If the subject has unstable hemod ynamics, or has any clinically  significant dysrhythmias 
noted on telemetry , the subject should be immediately  transferred to an acute care setting for 
definitive therap y.  
A study  cardiologist should be arranged by the Principal Investigator to be available as 
needed to review ECG tracings with abnormalities.
Body Temperature
Body temperature will be measured. The same method must be used for all measurements for 
each individual subject and should be the same for all subjects.
Vital Sign Measurements (Heart Rate and Blood Pressure)
Subjects should be resting in a semi -recumbent position for at least 10 minutes prior to 
having vital sign measureme nts obtained.  Semi-recumbent vital signs will include heart rate 
(HR) and blood pressure (BP).  The correct size of the blood pressure cuff and the correct 
positioning on the subjects' arm is essential to increase the accuracy  of blood pressure 
measurements.
The predose (baseline) HR and BP will be triplicate measurements obtained at least 1-2 
minutes apart within 60minutes of dosing MK-5160/glargine.  Themean of these 
measurements will be used as the baseline to calculate change from baseline for safet y 
evaluations (and for rechecks, if needed).  
Orthostatic vital signs (HR and BP) will also be obtained.  Subjects should be semi -
recumbent for at least 10 minu tes and then stand upright for 2 minutes prior to measurement 
of orthostatic vital signs.  
  04M9RT 
  04W8J9
Product:   MK-5160 45
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialGlucose Clamp
The glucose clamp technique will be applied in thisstudy , with each subject receiving an 
infusion of exogenous glucose (20% dextrose) during and after study  drug administration. 
Glucose infusions will be adjusted to maintain a stable plasma glucose target in the 
euglycemic range ( 100 mg/dL ). The clamp will be maintained to characterize washout of the 
PD effect and to ensure safet y.  The clamp will be discontinued at the discretion of the 
investigator when the GIR appears stable which may extend to 24 hours or longer after the 
initiation.
Plasma glucose concentrations will be frequently  measured by  bedside analy sis as a guide for 
adjusting the rate of glucose infusion. Additional details are provided in the Study  Operations 
Manual.
Laboratory Procedures/Assessments 7.1.3
Details regarding specific laboratory  procedures/assessments to be performed in this trial are 
provided below. The total amount of blood/ tissue to be drawn/collected over the course of 
the trial (from pre-trial to post-trial visits), including approximate blood/tissue volumes 
drawn/collected b y visit and by sample type per subject can be found in Section 12.3.
Laboratory Safety Evaluations (Hematology, Chemistry and Urinalysis) 7.1.3.1
Laboratory  tests for hematology , chemistry  and urinaly sis are specified in Table 5.
Table 5Laboratory  Tests
Hematology Chemistry Urinalysis Other
Hematocrit Albumin Blood Follicle Stimulating 
Hormone (FSH)
Hemoglobin Alkaline phosphatase Glucose Hepatitis B/C 
Screening
Platelet count Alanine aminotransferase 
(ALT)Protein HIV
WBC (total and 
differential)Aspartate aminotransferase 
(AST)Specific gravit y Urine Drug Screen
Bicarbonate Microscopic exam, 
if abnormal results 
are notedBreath alcohol 
assessment 
Calcium C-peptide
Chloride Nonesterified Fatty 
Acids (NEFA).  Also 
known as Free Fatty 
Acids (FFA).
Creatinine Ketones (β-
hydroxybutyric acids )
Glucose Glycerol
Magnesium Glucagon
Potassium Trigl ycerides 
  04M9RT 
  04W8J9
Product:   MK-5160 46
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialHematology Chemistry Urinalysis Other
Sodium
Total Bilirubin  
Direct Bilirubin, if total 
bilirubin is elevated above 
the upper limit of normal
Total protein
Blood Urea Nitrogen
Pre-trial (screening) and post -trial laboratory  safety  tests will be performed after at least an 8 -
hour fast.  Fasting is required for the pre-dose (Day  -1) laboratory  safety  tests. Pre-dose 
laboratory  proc edures can be conducted up to 30 hours prior to dosing, and must be reviewed
(with the exception of C-peptide, insulin, NEFA, ketones , glucagon, and glycerol) prior to 
dosing on Day  1.
Pharmacokinetic/Pharmacodynamic Evaluations 7.1.3.2
The decision as to which plasma and/or urine samples collected will be assay ed for 
evaluation of pharma cokinetics/pharmacod ynamics will be collaborativel y determined by the 
Department of Quantitative Pharmacology  and Pharmacometrics (QP2) and the appropriate 
department within Early -Stage Development, (e.g., samples at lower doses may not be 
assay ed if sampl es at higher doses reveal undetectable drug concentrations).  If indicated, 
these samples may also be assay ed and/or pooled for assay  in an exploratory  manner for 
metabolites and/or additional pharmacod ynamic markers.
7.1.3.2.1 Blood Collection for Plasma MK-5160
Sample collection, storage and shipment instructions for plasma samples will be provided in 
theoperations/laboratory manual. 
7.1.3.2.2 Blood Collection for Glargine
Sample collection, storage and shipment instructions for plasma samples will be provided in 
the operations/laboratory manual .
7.1.3.2.3 Blood Collection for Plasma Glucose (Bedside Analysis)
Ambient glucose concentrations from plasma will be recorded frequentl y (approximately  5 
minutes apart) by GlucoScout, or equivalent, at the bedside per site operating procedures to 
guide titration of glucose infusions in achieving specified glycemic target levels.  Additional 
glucose measurements will be assessed using Yellow Springs Instrument (YSI ) per the study 
operations manual.
Glucose infusion rates will be record ed frequently  throughout the infusion/clamp procedure 
per site standard operating procedures. 
  04M9RT 
  04W8J9
Product:   MK-5160 47
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidential7.1.3.2.4 Blood Collection for Anti -MK-5160 and Anti -Glargine (Insulin) 
Antibody/Immunogenicity Assay
Serum samples will be collected to assess the presence of anti-MK- 5160/insulin antibodies. 
Sample collection, storage and shipment instructions for serum samples will be provided in 
the operations/laboratory manual.
Planned Genetic Analysis Sample Collection 7.1.3.3
Sample collection, storage and shipment instructions for Planned Genetic Anal ysis samples 
will be provided in the operations/laboratory manual.
Future Biomedical Research Sample s 7.1.3.4
The following specimens are to be obtained as part of Future Biomedical Research:
DNA for future research
Leftover main study  plasma from MK- 5160 and/ormetabolites or glargine stored 
for future research.
Other Procedures 7.1.4
Withdrawal/Discontinuation 7.1.4.1
The investigator or trial coordinator must notify  the Sponsor when a subject has been 
discontinued/withdrawn from the trial.  If a subject discon tinues for any reason at any time 
during the course of the trial, the subject may be asked to return to the clinic (or be 
contacted) for a post-trial visit (approximately  14 days after the last protocol -specified 
procedure is performed ) to have the applicable procedures conducted.  However, the 
investigator may decide to perform the post-trial procedures at the time of discontinuation or 
as soon as possible after discontinuation.  If the post-trial visit occurs prior to 14 days after 
the last protocol -speci fied procedure is performed , the investigator should perform a follow -
up phone call 14 days after the last protocol -specified procedure to determine if any adverse 
events have occurred since the post -trial clinic visit.  Any  adverse events which are presen t at 
the time of discontinuation/withdrawal should be followed in accordance with the safety  
requirements outlined in Section 7.2 -Assessing and Recording Adverse Events.
7.1.4.1.1 Withdrawal From Future Biomedical Research
Subjects may withdraw their consent for Future Biomedical Research .  Subjects may 
withdraw consent at any time by contacting the principal investigator for the main trial.  If 
medical records for the main trial are still available, the investigator will contact the Sponsor 
using the designated mailbox .  Subsequently , 
the subject's consent for Future Biomedical Research will be withdrawn .  A letter will be sent 
from the Sponsor to the investigator confirming the withdrawal . It is the responsibility  of the 
investigator to inform the subject of completion of withdrawal .  Any analyses in progr ess at 
the time of request for withdrawal or alread y performed prior to the request being received 
by the Sponsor will continue to be used as part of the overall research trial data and results.  
No new analy ses would be generated after the request is rece ived. 
  04M9RT
PPD 
  04W8J9
Product:   MK-5160 48
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialIn the event that the medical records for the main trial are no longer available (e.g., if the 
investigator is no longer required by regulatory  authorities to retain the main trial records) or 
the specimens have been completely  anony mized, there will no longer be a link between the 
subject’s personal information and their specimens.  In this situation, the request for 
specimen withdrawal cannot be processed.
7.1.4.1.2 Lost to Follow -up
If a subject fails to return to the clinic for a required study  visit and/or if the site is unable to 
contact the subject, the following procedures are to be performed:
The site must attempt to contact the subject and reschedule the missed visit.  If the 
subject is contacted, the subject should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
The investigator or designee must make every  effort to regain contact with the 
subject at each missed visit (e.g. phone calls and/or a certified letter to the 
subject’s last known mailing address or locally  equivalent methods). These 
contact attempts should be documented in the subject’s medical record.
Note:  A subject is not considered lost to follow up until the last scheduled visit 
for the individual subject.  The amount of missing data for the subject will be 
managed via the pre -specified data handling and analy sis guidelines
Subject Blinding/Unblinding 7.1.4.2
When the investigator or delegate needs to identify  the drug used by a subject in case of 
emergency  e.g., the occurrence of serious adverse events , he/she will contact the emergency  
unblinding call center by telephone and make a request for emergency  unblinding.  As 
requested by the investigator or delegate the emergency  unblinding call center will provide 
the information to him/her promptly  and report unblinding to the Sponsor .  Prior to 
contacting the emergency  unblinding call center to request unblinding of a subject’s 
treatment assignment, the investigator or delegate must enter the intensity /toxicity  grade of 
the adverse event s observed, the relation to study  drug, the reason thereof, etc., in the medical 
chart etc. Subjects whose treatment assignment has been unblinded by the 
investigator/delegate and/or non-study  treating physician must be discontinued from study  
drug, but should continue to be monit ored in the trial .
Treatment/Vaccine identification information is to be unmasked ONLY if necessary  for the 
welfare of the subject.  Every effort should be made not to unblind the subject unless 
necessary . 
In the event that unblinding has occurred, the circumstances around the unblinding (e.g., 
date, reason and person performing the unblinding ) must be documented promptly , and the 
Sponsor Clinical Director notified as soon as possible. Only  the principal investigator or 
delegate and the respective subject’ s code should be unblinded. Other t rial site personnel and 
Sponsor personnel directly associated with the conduct of the trial should not be unblinded.
At the end of the trial, random code/disclosure envelopes or lists and unblinding logs are to 
be returne d to the Sponsor or designee. 
  04M9RT 
  04W8J9
Product:   MK-5160 49
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialDomiciling 7.1.4.3
Subjects will report to the clinical research unit (CRU) on Day -4 prior to the scheduled day 
of trial drug administration on Day  1 and remain in the unit until Day  14.  At the discretion of 
the investigator, subjects may  be requested toremain in the CRU longer.
Calibration of Critical Equipment 7.1.4.4
The investigator or qualified designee has the responsibility  to ensure that any critical device
or instrument used for a clinical evaluation/test during a clinical trial that provides important 
information about inclusion/exclusion criteria and/or safet y or efficacy  parameters shall be 
suitably  calibrated and maintained to ensure that the data obtained is reliable and/or 
repro ducible.  Documentation of equipment calibration must be retained as source 
documentation at the trial site.
Critical Equipment for this trial includes:
ECG machine, equipment for Vital Signs measurements, glucometers, Yellow Springs 
Instrument (YSI) gluco se analyzer, GlucoScout, and syringe/infusion pumps for 
administering glucose and study  drugs.
Visit Requirements 7.1.5
Visit requirements are outlined in Section 6.0-Trial Flow Chart. Specific procedure -related 
details are provided above in Section 7.1 -Trial Procedures.
Screening 7.1.5.1
Within 30 days prior to day 1, potential subjects will be evaluated to determine that they 
fulfill the entry  requirements as set forth in Section 5.1.
Subjects may be rescreened after consultation with the Sponsor. Rescreening should include 
all screening procedures listed in the protocol flow chart, including consent review. Rescreen 
procedures cannot be conducted the day prior to treatment allocation/ randomization if there 
are Day  -1 procedures planned per protocol.
Treatment Period Visit 7.1.5.2
Subcutaneous MK-5160 or glargine will be administered as a daily  injection from Day 1 to 
Day 12.
Exogenous glucose will also be infused concurrently  with adjustments as needed to maintain 
a stable glucose concentration predefined by  the subject’s baseline fasting glucose during the 
clamp procedure and longer if necessary . Details of this euglycemic clamp technique are 
outlined in the Study  Operations Manual.
Post-Trial 7.1.5.3
Subjects will be required to return to clinic approximately  16days (+/ 3days)after the last 
dose of trial drug for the post-trial visit.  If the post-trial visit occurs less than 16days after 
the last dose of trial drug, a subsequent follow -up phone call should be made at 16days post 
the last dose of trial drug to determine if any  adverse events have occurred since the post -trial  
  04M9RT 
  04W8J9
Product:   MK-5160 50
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidentialclinic visit. Subjects will be required to return to clinic approximately  16days (+/- 3days)
post final dose (Day  28) for collection of additional anti-drug antibodies (ADA) and anti-
insulin antibodies (AI A) samples.
If a subject has a positive titer at the 28 day follow -up visit, an additional sample will be
drawn approximately  56 day s (+/ -5 day s) after the completion of dosing. At the same time , a
fasting plasma glucose sample will be drawn from the subject and an evaluation of possible
signs and symptoms of hypergly cemia will be conducted . If medicall yrequired the subject 
will be referred to an endocrinologist for further treatment.
Additional follow -ups will be conducted in intervals of approximately  3 m onths (+/-5 days)
in subjects with detectable ADAs /AIAs until one of the following occurs:
a)subject no longer has detectable ADAs /AIAs ,
b)ADAs /AIAs are persistent and stable (titers within 2 to 3-fold of each other) on 3 
consecutive checks at 3 month intervals,
c)return to baseline levels (i.e., within 2 to 3 -fold of predose)
An additional fasting plasma glucose sample will be drawn at each time subjects return for
ADA /AIA follow -up, and an evaluation of possible signs and symptoms of hypergl ycemia 
will be conducted. Subjects will be referred to an endocrinologist if medically  required.
Critical Procedures Based on Trial O bjectives: Timing of Procedure 7.1.5.4
For this trial, the blood sample collection for MK-5160 and glargine isthe critical procedure
as is the glucose clamp procedure . 
At any post-dose timepoint, the blood sample for MK- 5160 needs to be collected as close to 
the exact timepoint as possible.  All other procedures should be completed as close to the 
prescribed/scheduled time as possible. Trial procedures can be performed prior or after the 
prescribed/scheduled time.  
The order of priorit y can be changed during the trial with joint agreement of the investigator 
and the Sponsor Clinical Director .  
Any nonscheduled procedures required for urgent evaluation of safety  concerns take 
precedence over all routine scheduled procedures. 
The following variance in procedure collection times will be permitted.
PK Collection as outlined in Table 6below
Table 6PK (Blood) Collection Windows
PK collection relative to dose PK Collection Window
hr +/-5 min
˃ 1hr +/-15 min
24 hr (daily) +/-30 min
> 48 hr after last dose +/-2 hours 
  04M9RT 
  04W8J9
Product:   MK-5160 51
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialNon- clamp day standard safet y evaluations:  (vital signs & ECG) -+/- 3 hrs
(predose) ; (laboratory  safety  tests & phy sical exam) -  +/-6 hrs
Clamp day standard safety  evaluations (vital signs, ECG, laboratory  safet y tests, 
physical exam):  +/-30 mins
Pharmacod ynamic or other protocol specific measurements, or modification to any of 
the above windows:  
oNEFA, gl ycerol, glucagon, trigl ycerides, C-peptide, and endogenous insulin: 
+/-30 minutes
oADA/AIA: +/-6 hours
Study  drug administration:  +/-30 mins
Trial Design/Dosing/Procedures Modifications Permitted within Protocol 7.1.5.5
Parameters
This is a Phase I assessment of MK- 5160 in humans, and the pharmacokinet ic, 
pharmacod ynamic and safet y profiles of the compound is still being elucidated.  This 
protocol is written with some flexibility  to accommodate the inherent dynamic nature of 
Phase I clinical trials.  Modifications to the dose, dosing regimen and/or clin ical or laborator y 
procedures currently  outlined below may be required to achieve the scientific goals of the 
trial objectives and/or to ensure appropriate safet y monitoring of the trial subjects.  
As such, some alterations from the currently  outlined dose and/or dosing regimen may be 
permitted based on newly available data, but the maximum daily  dose may not exceed those 
currentl y outlined in the protocol.
Repeat of or decrease in the dose of the trial drug administered in any given 
period/panel
Interchan ge of doses between panels
Entire period(s) or panel(s) may  be omitted
Decrease in the duration of trial drug administration (e.g. ,number of day s) 
Remove a planned pharmacokinetic pause if agreed by  Sponsor and investigator if no 
further increases in tot al daily  dose
Addition of pharmacokinetic pause
Addition of operational pause
Decrease in the target glycemic level to be maintained during glucose infusion/clamp 
procedure
Decrease in number of PK sampling timepoints
Modification of the PK/PD sample processing and shipping details based on newly 
available data
Modification of urin e sample collection to another panel or period 
  04M9RT 
  04W8J9
Product:   MK-5160 52
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialThe pharmacokinetic/pharmacod ynamic sampling scheme currently  outlined in the protocol 
may be modified during the trial based on newl y available pharmacokinetic or 
pharmacod ynamic data (e.g., to obtain data closer to the time of peak plasma concentrations).  
If indicated, these collected samples may also be assay ed in an exploratory  manner for 
metabolites and/or additional pharmac odynamic markers.
Up to additional 50 mL  (NOTE:  Never more than 50 mL) of blood may  be drawn for safety , 
pharmacokinetic, and/or pharmacod ynamic analy ses.  The total blood volume withdrawn 
from any single subject will not exceed the maximum allowable volume during his/her 
participation in the entire trial ( Section 12.3). 
The timing of procedures for assessment of safety  procedures (e.g., vital signs, ECG, safet y 
laboratory  tests, etc.) currentl y outlined in the protocol may be modified during the trial 
based on newl y available safet y, tolera bility , pharmacokinetic or pharmacody namic data 
(e.g., to obtain data closer to the time of peak plasma concentrations).  Additional laboratory 
safet y tests may be added to blood samples previously  drawn to obtain additional safet y 
information (e.g., addin g creatinine kinase to serum chemistry  panel that was alread y drawn. 
These changes will not increase the number of trial procedures for a given subject during 
his/her participation in the entire trial. 
It is understood that the current trial may employ some or none of the alterations described 
above.  Any alteration made to this protocol to meet the trial objectives must be detailed by 
the Sponsor in a letter to the Trial File and forwarded to the investigator for retention.  The 
letter may be forwarded to the IRB/IECat the discretion of the investigator.
Assessing and Recording Adverse Events 7.2
An adverse event is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not necessarily 
have to have a causal relationship with this treatment. An adverse event can therefore be any 
unfavourable and unintended sign (including an abnormal laboratory  finding, for example), 
symptom, or disease temporally  associated with the use of a medicinal product or protocol -
specified procedure, whether or not considered related to the medicinal product or protocol -
specified procedure.  Any worsening (i.e., any clinically  significant adverse change in 
frequency  and/or intensity ) of a preexisting condition that is temporally  associated with the 
use of the Sponsor’s product, is also an adverse event.
Changes resulting from normal growth and development that do not vary significantl y in 
frequency  or severit y from expected levels are not to be consid ered adverse events.  
Examples of this may include, but are not limited to, teething, typical crying in infants and 
children and onset of menses or menopause occurring at a ph ysiologically  appropriate time.
Sponsor's product includes any pharmaceutical product, biological product, device, 
diagnostic agent or protocol -specified procedure, whether investigational (including placebo 
or active comparator medication) or marketed, manufactured by, licensed by, provided by or 
distributed by  the Sponsor for human u se.
Adverse events may occur during clinical trials, or as prescribed in clinical practice, from 
overdose (whether accidental or intentional), from abuse and from withdrawal. 
  04M9RT 
  04W8J9
Product:   MK-5160 53
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialFor randomized subjects only, all adverse events that occur after the consent form is signed 
but before treatment allocation/ randomization must be reported by  investigator if they  are the 
result of a protocol -specified intervention, including but not limit ed to washout or 
discontinuation of usual therap y, diet, placebo treatment or a procedure. From the time of 
treatment allocation/ randomization through 19days following cessation of treatment, (5 days 
after Day 28)all adverse events must be reported by the investigator. Such events will be 
recorded at each examination on the Adverse Event case report forms/worksheets.  The 
reporting timeframe for adverse events meeting any serious criteria is described in section 
7.2.3.1. The investigator will make every attempt to follow all subjects with non-serious 
adverse events for outcome.
Electronic reporting procedures can be found in the Electronic Data Capture (EDC )data 
entry  guidelines. Paper reporting procedures can be found in the Investigator Trial File 
Binde r (or equivalent).
Definition of an Overdose for This Protocol and Reporting of Overdose to the 7.2.1
Sponsor
The subject has taken (accidentally  or intentionally ) any drug administered as part of the 
protocol and exceeding the dose as prescribed by the protocol . It is up to the investigator or 
the reporting physician to decide whether a dose is to be considered an overdose, in 
consultation with the Sponsor.
If an adverse event(s) is associated with (“results from”) the overdose of Sponsor's product or 
vaccine, the adverse event(s) is reported as a serious adverse event, even if no other 
seriousness criteria are met.
If a dose of Sponsor's product or vaccine meeting the protocol definition of overdose is taken 
without any associated clinical symptoms or abnormal laboratory  results, the overdose is 
reported as a non-serious Event of Clinical Interest (ECI ), using the terminology  “accidental 
or intentional overdose without adverse effect.”
All reports of overdose with and without an adverse event must be reported by the 
investigator within 24 hours to the Sponsor either by electronic media or paper. Electronic 
reporting procedures can be found in the EDC data entry  guidelines. Paper reporting 
procedures can be found in the I nvestigator Trial File Binder (or equivalent ).
Reporting of Pregnancy and Lactation to the Sponsor 7.2.2
Although pregnancy  and lactation are not considered adverse events, it is the responsibility  of 
investigators or their designees to report any pregnancy  or lactation in a subject 
(spontaneousl y reported to them), including the pregnancy  of a male subject's female partner 
that occurs during the trial .
Pregnancies and lactations of subjects and female partners of male subjects from the time the 
consent form is signed but before treatment allocation/ randomization must be reported by  the 
investigator if they cause the subject to be excluded from the trial, or are the result of a 
protocol -specified intervention, including but not limited to washout or discontinuation of 
usual therap y, diet, placebo treatment or a procedure.  Pregnancies and lactations of subjects 
and female partners of male subjects that occur from the time of treatment 
allocation/ randomization through 14 days following cessation of Sponsor’s product must be  
  04M9RT 
  04W8J9
Product:   MK-5160 54
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidentialreported. All reported pregnancies  must be followed to the completion/termination of the 
pregnancy . Pregnancy outcomes of spontaneous abortion, missed abortion, benign 
hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage and stillbirth 
must be rep orted as serious events (Important Medical Events). If the pregnancy  continues to 
term, the outcome (health of infant) must also be reported.
Such events must be reported within 24 hours to the Sponsor either by electronic media or 
paper. Electronic report ing procedures can be found in the EDC data entry guidelines. Paper 
reporting procedures can be found in the Investigator Trial File Binder (or equivalent).
Immediate Reporting of Adverse EventsAdverse Events and Incidents to the 7.2.3
Sponsor
Serious Adverse Ev ents 7.2.3.1
A serious adverse event is any adverse event occurring at any dose or during any use of 
Sponsor's product that:
●Results in death;
●Is life threatening;
●Results in persistent or significant disability /incapacity ;
●Results in or prolongs an existi ng inpatient hospitalization;
●Is a congenital anomal y/birth defect;
●Is an other important medical event .
Note: In addition to the above criteria, adverse events meeting either of the below criteria, 
although not serious per ICH definition, are reportable to the Sponsor in the same timeframe 
as SAEs to meet certain local requirements. Therefore, these events are co nsidered serious by 
the Sponsor for collection purposes.
●Is a cancer;
●Is associated with an overdose .
Refer to Table 7for additional details regarding each of the above criteria.
For the time period beginning when the consent form is signed until treatment 
allocation/ randomization, any serious adverse event, or follow up to a serious adverse event, 
including death due to any  cause, that occurs to any  subject must be reported within 24 hours 
to the Sponsor if it causes the subject to be excluded from the trial, or is the result of a 
protocol -specified intervention, including but not limited to washout or discontinuation of 
usual therap y, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/ randomization through 19days 
following cessation of treatment (5 days after Day 28), any serious adverse event, or follow 
up to a serious adverse event, including death due to any cause, whether or not related to the 
Sponsor's product, must be reported within 24 hours to the Sponsor either by electronic 
media or paper. Electronic reporting procedures can be found in the EDC data entry  
guidelines. Paper reporting procedures can be found in the Investigator Trial File Binder (or 
equivalent). 
  04M9RT 
  04W8J9
Product:   MK-5160 55
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialAdditionally , any serious adverse event, considered by an investigator who is a qualified 
physician to be related to the Sponsor's product that is brought to the attention of the 
investigator at any time outside of the time period specified in the previous paragraph also 
must be reported i mmediately  to the Sponsor.
All subjects with serious adverse events must be followed up for outcome.
Events of Clinical Interest 7.2.3.2
Selected non-serious and serious adverse events are also known as Eve nts of Clinical I nterest 
(ECI) and must be reported to th e Sponsor.
For the time period beginning when the consent form is signed until treatment 
allocation/ randomization, any  ECI, or follow up to an ECI , that occurs to any  subject must be 
reported within 24 hours to the Sponsor if it causes the subject to be excluded from the trial, 
or is the result of a protocol -specified intervention, including but not limited to washout or 
discontinuation of usual therap y, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/ randomizat ion through 14days 
following cessation of treatment, any ECI, or follow up to an ECI, whether or not related to 
the Sponsor’s product, must be reported within 24 hours to the Sponsor, either by electronic 
media or paper.  Electronic reporting procedures can be found in the EDC data entry 
guidelines.  Paper reporting procedures can be found in the Investigator Trial File Binder (or 
equivalent).
Events of clinical interest for this trial include:
1. an overdose of Sponsor's product, as defined in Section 7. 2.1 -Definition of an Overdose 
for This Protocol and Reporting of Overdose to the Sponsor, that is not associated with 
clinical symptoms or abnormal laboratory  results. 
2. an elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of 
normal and an elevated total bilirubin lab value that is greater than or equal to 2X the 
upper limit of normal and, at the same time, an alkaline phosphatase lab value that is less 
than 2X the upper limit of normal, as determined by way  of protocol -specified laboratory  
testing or un scheduled laboratory  testing.*
*Note:  These criteria are based upon available regulatory  guidance documents. The 
purpose of the criteria is to specify  a threshold of abnormal hepatic tests that must trigger 
an additional evaluation for an underl ying etiology. The trial site guidance for assessment 
and follow up of these criteria can be found in the Investigator Trial File Binder (or 
equivalent).
It may also be appropriate to conduct additional evaluation for an underl ying etiology  in 
the setting of abnormalities of liver blood tests including AST, ALT, bilirubin, and 
alkaline phosphatase that do not meet the criteria noted above. In these cases, the decision 
to proceed with additional evaluation will be made through consult ation between the 
study  investigators and the Sponsor Clinical Director. However, abnormalities of liver 
blood tests that do not meet the criteria noted above are not ECIs for this trial . 
  04M9RT 
  04W8J9
Product:   MK-5160 56
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidential1.any suspected allergic reaction, including the following:
Any skinreaction, skin eruption, and/or rash occurrence in a study  subject 
following administration of study  drug,
Study -drug related systemic reactions or study drug -related hypersensitivity  
reactions (e.g., anaph ylaxis, angioedema).
Evaluating Adverse Events 7.2.4
An investigator who is a qualified physician will evaluate all adverse events with respect to 
the elements outlined in Table 7. The investigator’s assessment of causality  is required for 
each adverse event.  Refer to Table 7for instructions in evaluating adverse events. 
  04M9RT 
  04W8J9
Product:   MK -5160 57
Protocol/Amendment No.: 002-00 
MK-5160-002- 00 Final Protocol 27-Feb-2017
ConfidentialTable 
7Evaluating Adverse Events
Maximum Mild awareness of sign or symptom, but easily tolerated  (for pediatric trials, awareness of symptom, but easily tolerated)
Intensity Moderate discomfort enough to cause interference with usual activity (for pediatric trials, definitely acting like something is wrong)
Severe incapacitating with inability to work or do usual activity (for pediatric trials, extremely distressed or unable to do usual activities)
Seriousness A serious adverse event (AE) is any adverse event occurring at any dose or during any use of Sponsor's product that:
†Results in death ; or
†Is life threatening; or places the subject, in the view of the investigator, at immediate risk of death from the event as it occurred [Note: This does not include an 
adverse event  that, had it occurred in a more severe form, might have caused death.]; or
†Results in a persistent or significant disability/incapacity (substantial disruption of one’s ability to conduct normal life functions); or
†Results in or prolongs an existing inpatient hospitalization (hospitalization is defin ed as an inpatient admission, regardless of length of stay, even if the 
hospitalization is a precautionary measu re for continued observation.  ( Note: Hospitalization for an elective procedure to treat a pre-existing condition that has not 
worsened is not a serious adverse event.  A pre -existing condition is a clinical condition that is diagnosed prior to the use of a Merck product and is documented in the 
patient’s medical history. ); or
†Is a congenital anomaly/birth defect  ( in offspring of subject taking the product regardless of time to diagnosis); or
Is a cancer (although not serious per IC Hdefinition, is reportable to the Sponsor within 24 hours to meet certain local requirements) ;or
Is associated with an overdose (whether accidental or intentional).  Any adverse event associated with an overdose is considered a serious adverse event for 
collection purposes . An overdose that is not associated with an adverse event is considered a non-serious event of clinical interest and must be reported within 24 
hours.
Other important medical events that may not result in death, not be life threatening, or not require hospitalization may be considered a serious adverse event when, 
based upon appropriate medical judgment, the event may jeopardize the s ubject and may require medical or surgical intervention to prevent one of the outcomes listed 
previously (designated above by a †).
Duration Record the start and stop dates of the adverse event.  If less than 1 day, indicate the appropriate length of time and units
Action taken Did the adverse event cause the Sponsor's product to be discontinued?
Relationship to 
Sponsor's 
ProductDid the Sponsor's product cause the adverse event? The determination of the likelihood that the Sponsor's product caused theadverse event will be provided by an 
investigator who is a qualified physician.  The investigator’s signed/dated initials on the source document or worksheet thatsupports the causality noted on the AE 
form, ensures that a medically qualified assessment of causality was done.  This initialed document must be retained for the required regulatory time frame.  The 
criteria below are intended as reference guidelines to assist the investigator in assessing the likelihood of a relationship between the test drug and the adverse event 
based upon the available information
The following components are to be used to assess the relationship between the Sponsor's product and the AE ; the greater the correlation with the components 
and their respective elements (in number and/or intensity), the more likely the Sponsor's product caused the adverse event:
Exposure Is there evidence that the subject was actually exposed to the Sponsor's product such as:  reliable history, acceptable compl iance assessment (pill 
count, diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite in bodily specimen?
Time Course Did the AE follow in a reasonable temporal sequence from administration of the Sponsor's product? 
Is the time of onset of the AE compatible with a drug-induced effect (applies to trials with investigational medicinal product)?
Likely Cause Is the AE not reasonably explained by another etiology such as underlying disease, other drug(s)/vaccine(s), or other host orenvironmental 
factors 
  04M9RT 
  04W8J9
Product:   MK -5160 58
Protocol/Amendment No.: 002-00 
MK-5160-002- 00 Final Protocol 27-Feb-2017
ConfidentialRelationship The following components are to be used to assess the relationship between the Sponsor's product and the AE:  (continued)
to Sponsor's 
Product
(continued) Dechallenge Was the Sponsor's product discontinued or dose/exposure/frequency reduced?
      If yes, did the AE resolve or improve?
           If yes, this is a positive dechallenge.    If no, this is a negative dechallenge.
(Note:  This criterion is not applicable if:  (1) the AE resulted in death or permanent disability; (2) the AE resolved/impro ved despite 
continuation of the Sponsor's product; (3) the trial is a single -dose drug trial); or (4) Sponsor's product(s) is/are only used one time.)
Rechallenge Was the subject re- exposed to the Sponsor's product in this trial?
      If yes, did the AE recur or worsen?
          If yes, this is a positive rechallenge.    If no, this is a negative rechallenge.
(Note:  This criterion is not applicable if:  (1) the initial AE resulted in death or permanent disability, or (2) the tri al is a single -dose drug trial); 
or (3) Sponsor's product(s) is/are used only one time.)
NOTE:  IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS SERIOUS AND WHICH MAY HAVE BEEN 
CAUSED BY THE SPONSOR'S PRODUCT, OR IF RE -EXPOSURE TO THE SPONSOR'S P RODUCT POSES ADDITIONAL POTENTIAL 
SIGNIFICANT RISK TO THE SUBJECT THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY THE SPONSOR
CLINICAL DIRECTOR AND THE INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE.
Consistency 
with Trial 
Treatment 
ProfileIs the clinical/pathological presentation of the AE consistent with previous knowledge regarding the Sponsor's product or dru g class 
pharmacology or toxicology?
The assessment of relationship will be reported on the case report forms /worksheets by an inv estigator who is a qualified physician according to his/her best clinical judgment, including 
consideration of the above elements.
Record one of the following : Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a Sponsor's product relationship).
Yes, there is a reasonable 
possibility of Sponsor's product 
relationship.There is evidence of exposure to the Sponsor's product.  The temporal sequence of the AE onset relative to the administration of theSponsor's 
product is reasonable.  The AE is more likely explained by the Sponsor's product than by another cause. 
No, there is not a reasonable 
possibility of Sponsor's product 
relationshipSubject did not receive the Sponsor's product OR temporal seque nce of the AE onset relative to administration of the Sponsor's product is not 
reasonable OR the AE is more likely explained by another cause than the Sponsor’s product .  (Also entered for a subject with overdose without 
an associated AE.) 
  04M9RT 
  04W8J9
Product:   MK-5160 59
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialSponsor Responsibility for Reporting Adverse Events 7.2.5
AllAdverse Events will be reported to regulatory authorities, IRB/IECs andinvestigators in 
accordance with all applicable global laws and regulations , i.e., per ICH Topic E6 (R1) 
Guidelines for Good Clinical Practice .
8.0STATISTICAL ANALYSIS PLAN
Statistical Analysis Plan Summary 8.1
This section contains a brief summary  of the statistical analyses for this trial. Full detail s can 
be found beginning in Section 8.2).
Statistical Methods
Safety :
Incidence of adverse experiences will be descriptively  summarized.  Summary  statistics and 
plots will be generated for the change from baseline values in the vital signs, ECG 
parameters, and selected laboratory  safety parameters for subjects, as deemed clinicall y 
appropriate.  Depending on the safety  parameter, the difference from baseline will either be 
computed on the original scale (raw change from baseline) or on the log scale and back -
transformed for reporting (percent change from baseline).  Summary  statistics for the raw 
laboratory  safety tests, ECGs, and/or vital signs may also be computed, as deemed clinicall y 
appropriate.   Results will be summarized separately  by study  part.
Pharmacod ynamics
Individual maximal GIR values (GIRmax) based on LOESS smoothed data will be analy zed 
in a linear mixed effects model with fixed effects for treatment (i.e. glargine, MK-5160 Dose 
Level 1, MK-5160 Dose Level 2, MK-5160 Dose Level 3), day (Day 1, Day 12) and 
treatment by day interaction, a continuous covariate for BMI,and a random effect for 
subject.  A separate model will be used for each patient population (T1DM, T2DM).
GIRmax means and 95% confidenc e intervals for each treatment/day  will be calculated from 
the model.  To test the primary  hypothesis, the posterior probability  that the true mean 
GIRmax level at stead y state is within 1.5 and 4.5 mg/kg/min will be calculated for each 
MK- 5160 dose on Day 12 using a non -informative prior .  If this posterior probability  exceeds 
70% for at least one safe and well tolerated dose of MK-5160 for each population, then the 
primary  research h ypothesis will be supported.  
Between treatment GIRmax comparisons (MK-5 160 versus glargine) will be performed for 
each dose of MK -5160 and on each day , using the model.  
Pharmacokinetics 
Non- compartmental Analy sis (NCA) based geometric means and 95% confidence intervals 
will be provided for Cmax, AUC0 -24hr, Css and CL by treatment , dayand population.  The 
geometric mean accumulation ratio (Day 12PK / Day 1 PK) and 90% CI will be calculated 
for Cmax and AUC0 -24hr.
Scatterplots of individual PK values ( Stead y state AUC0 -24hr, Cmax, Css) versus BMI will 
be plotted for each patient population.  
  04M9RT 
  04W8J9
Product:   MK-5160 60
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialIndividual values will be listed for each PK parameter by treatment and day and the 
additional following (NCA -based) descriptive statistics will be provided: N (number of 
subjects with non-missing data), arithmetic mean, standard deviation, arithmetic percent CV 
(calculated as 100 x standard deviation/arithmetic mean), median, minimum, maximum, 
geometric mean, an d geometric percent CV (calculated as 100 x sqrt(exp(s2) -1), where s2 is 
the observed variance on the natural log-scale).  For Tmax, only median, minimum and 
maximum will be calculated.  
Pharmacokinetic endpoints following administration with glargine may be summarized in a 
similar fashion, as appropriate.
Power
Pharmacod ynamics 
This is the first study  of MK-5160 in a diabetic patient population, and as such no variance 
estimates exist other than those from a single dose study  in normal healthy  voluntee rs (P001).  
In order to provide an approximate estimate of power, the variability  observed in P001 has 
been used for the power calculations presented below (Table 8).  
 
Table 8  Probability  of Supporting Primary  PD Hy pothesis
Target GIRmax 
(mg/kg/min)True GIRmaxProbability of 
Supporting 
Hypothesis
(1.5, 4.5 ) 1 2%
1.5 30%
2 86%
2.5 99%
3 99%
3.5 99%
4 86%
4.5 30%
5 2%
The calculations above were based on  
 and N=6 per dose, and a posterior probability threshold 
of 70%.
Responsibility for Analyses 8.2
The statistical anal ysis of the data obtained from this study  will be conducted by , or under the 
direct auspices of, the Clinical Pharmacology  Statistics Department in collaboration with the 
Quantitative Pharmacology  and Pharmacometrics (QP2), and Translationa l Pharmacology  
Departments of the Sponsor. 
  04M9RT
CCI
CCI 
  04W8J9
Product:   MK-5160 61
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialIf, after the study  has begun, changes are made to the statistical analysis plan stated below, 
then these deviations to the plan will be listed, along with an explanation as to why they 
occurred, in the Clinical S tudy Report.
Hypotheses/Estimation 8.3
Primary:
At a dose with sufficient safet y, the mean steady -state maximum level of GIR (GIRmax) 
after MK-5160 administration in both T1 and T2 DM patients is between 1.5 and 4.5 
mg/kg/min.
Analysis Endpoints 8.4
Primary:
Safety
The primary  safety  endpoints in this study  will include all types of adverse experiences, in 
addition to laboratory  safety  assessments, ECGs, and vital signs.
Pharmacodynamics
The primary  pharmacody namic variable in this study  is the glucose infusio n rate (GIR) 
required to maintain plasma glucose at each subjects’ individual clamp target, following 
administration of MK-5160 or glargine .  To assess the primary  hypothesis, individual 
maximal GIR (GIRmax) values at stead y state (Day  12)will be used.  Prior to obtaining the 
maximal GIR values, data will be smoothed (LOESS) to minimize variability  and the 
potential impact of transient outliers influencing the estimation .  The default smoothing 
function in SAS PROC LOESS, which selects an optimal smoothing parameter based on 
minimizing a bias corrected AIC criterion, will be used to fit an optimal smoothing function 
for each subject.
Additional clamp endpoints that may be analyzed in a similar fashion as above include GIR 
AUC endpoints over the entire clamp timeframe (0-24 hours) as well as various subfractions 
of interest (e.g. 0-12, 12-24 hours and 24-end for the Day 12 clamp ), though these would be 
based on raw data and not LOESS smoothed .
Secondary:
Pharmacokinetics
The pharmacokinetic variables of inter est include Cmax, Css, Steady  State AUC0 -24hr, CL, 
Tmax and t1/2 of MK-5160 after SC administration.   Similar endpoints for glargine may  also 
be of interest, as appropriate.
Exploratory:
Pharmacodynamics
The exploratory  pharmacod ynamic endpoints in this study  include FFA,glycerol, 
triglycerides, β-hydroxybutyrate, glucagon and fasting morning glucose levels, following SC 
administration of MK -5160 or glargine.   Baseline is the Day  1 Predose value. 
  04M9RT 
  04W8J9
Product:   MK-5160 62
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialAnalysis Populations 8.5
The following populations are defined for the analy sis and reporting of data.  All subjects 
will be reported, and their data analy zed, according to the treatment(s) they actuall y received.
All Subjects as Treated (AST) – All subjects who received at leastone dose ofthe 
investigati onaldrug. Thispopulation willbeused for assessme ntsofsafetyandtolerability .
Per-Protocol (PP) –Thesetofdata generated bythesubset ofsubjects who co mplywith the 
protocol sufficiently toensure thatthese data willbe likely to exhibit the effects oftreatment , 
accor dingtotheunderly ingscient ificmodel. Compliance covers such consi derations as 
exposure to treatment, availab ility of measurements and absence of major protocol 
deviations .  Major protocol deviators will be identified tothe extent possible prior to 
unblinding byindividuals responsible fordata collection/c ompliance, and itsanalysis
and interpretation. Anysubjects ordata values excluded from analysiswill beidentified,
along with theirreason forexclusion, intheCSR. Attheend ofthestudy,allsubjects
who are compliant with thestudy procedure asaforemen tioned and have available data
from at least one treatmentwill beincluded intheprimaryanalysisdataset. This population
willbeused for thePKand PD analy ses.
Statistical Methods 8.6
Primary
Safety :
Incidence of adverse experiences will be descriptively  summarized.  Summary  statistics and 
plots will be generated for the change from baseline values in the vital signs, ECG 
parameters, and selected laboratory  safety parameters for subjects, as deemed clinicall y 
appropriate.  Depending on the safety  parameter, the difference from baseline will either be 
computed on the original scale (raw change from baseline) or on the log scale and back -
transformed for reporting (perc ent change from baseline).  Summary  statistics for the raw 
laboratory  safety tests, ECGs, and/or vital signs may also be computed, as deemed clinicall y 
appropriate.  Results will be summarized separately b y stud y part.
The incidence and nature of nighttime and other episodes of potential hypoglycemia, using 
fingerstick glucose levels and CGM data will be summarized using descriptive 
statistics. Modeling techniques may  be employ ed as needed.
Pharmacod ynamics
Individual maximal GIR values (GIRmax) based on LOESS smoothed data will be analy zed 
in a linear mixed effects model with fixed effects for treatment (i.e. glargine, MK-5160 Dose 
Level 1, MK-5160 Dose Level 2, MK-5160 Dose Level 3), day (Day 1, Day 12) and 
treatment by day interaction, a continuous covar iate for BMI, and a random effect for 
subject.  A separate model will be used for each patient population (T1DM, T2DM).
GIRmax means and 95% confidence intervals for each treatment/day  will be calculated from 
the model.  To test the primary  hypothesis, theposterior probability  that the true mean 
GIRmax level at stead y state is within 1.5 and 4.5 mg/kg/min will be calculated for each 
MK- 5160 dose on Day  12 using a non -informative prior.  If this posterior probability  exceeds  
  04M9RT 
  04W8J9
Product:   MK -5160 63
Protocol/Amendment No.: 002-00 
MK-5160-002- 00 Final Protocol 27-Feb-2017
Confidential7
0% for at least one safe and well tolerated dose of MK-5160 for each population, then the 
primary  research h ypothesis will be supported.  
Between treatment GIRmax comparisons (MK -5160 versus glargine) will be performed for 
each dose of MK -5160 and on each day , using the model.  
Additi onal clamp endpoints 
that may be analyzed in a similar fashion as above include GIR 
AUC endpoints over the entire clamp timeframe (0-24 hours) as well as various subfractions 
of interest (e.g. 0 -12, 12 -24 hours), though these would be based on raw data and not LOESS 
smoothed.
Secondary
Pharmacokinetics
NCA based geometric means and 95% confidence intervals will be provided for Cmax, 
AUC0 -24hr, Css and CL by treatment , day and population.  The geometric mean 
accumulation ratio (Day 12 PK / Day 1 PK) and 90% CI will be calculated for Cmax and 
AUC0 -24hr.
Scatterplots of individual PK values (Stead y state AUC0 -24hr, Cmax, Css) versus BMI will 
be plotted for each patient population. 
Individual values will be listed for each PK parameter by treatment and day and the 
additional following (NCA -based) descriptive statistics will be provided: N (number of 
subjects with non-missing data), arithmetic mean, standard deviation, arithmetic percent CV 
(calculated as 100 x standard deviation/arithmetic mean), median, minimum , maximum, 
geometric mean, and geometric percent CV (calculated as 100 x sqrt(exp(s2) -1), where s2 is 
the observed variance on the natural log-scale).  For Tmax, only median, minimum and 
maximum will be calculated.  
Pharmacokinetic endpoints following administration with glargine may be summarized in a 
similar fashion, as appropriate.
Exploratory
Pharmacod ynamics
Plasma FFA, glycercol, triglycerides, β-hydroxy butyrate, glucagon and fasting morning 
glucose levels, following SC administration of MK-5160 or glargine will be summarized 
with descriptive statistics and plotted over time. More formal treatment comparisons (MK -
5160 versus glargine) may  also be performed. Baseline is the Day  1 Predose value.
Pharmacokinetics/Pharmacod ynamics 
Exploratory  PK/PD plots linking PD measures (GIR, Glucose, FFA and other secondary  PD 
measures) to PK measures (concentration at different timepoints, Cmax, stead y state AUC0 -
24hr) may be plotted as deemed necessary . MK-5160 PK/PD relationship will be explored 
using an integrated PK/PD modeling approach as necessary . 
  04M9RT 
  04W8J9
Product:   MK-5160 64
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialMultiplicity 8.7
There is only one testable research hypothesis in this study .  Formal statistical testing with 
associated p-value cut-offs centered around controlling Type-I error rates will not be used in 
assessing this h ypothesis; hence no multiplicity adjustment is required or proposed.
Sample Size and Power Calculations 8.8
Pharmacod ynamics 
This is the first study  of MK-5160 in a diabetic patient population, and as such no variance 
estimates exist other than those from a single dose study  in normal healthy  volunteers (P001).  
In order to provide an approximate estimate of power, the variability  observed in P001 has 
been used for the power calculations presented below (Table 9).  
 
Table 9  Probability  of Supporting Primary  PD Hy pothesis
Target GIRmax 
(mg/kg/min)True GIR maxProbability of 
Supporting Hy pothesis
(1.5, 4.5) 1 2%
1.5 30%
2 86%
2.5 99%
3 99%
3.5 99%
4 86%
4.5 30%
5 2%
The calculations above were based  
and N=6 per dose, and a posterior 
probability threshold of 70%.
9.0LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL 
SUPPLIES
Investigational Product 9.1
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate suppl y, storage, handling, distribution and usage of 
investigational product in accordance with the protocol and any applicable laws and 
regulations.
Clinical Supplies will be provided b y the Sponsor as summarized in Table 10 
  04M9RT
CCI
CCI 
  04W8J9
Product:   MK-5160 65
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialClinical supplies will be packaged to support enrollment and replacement subjects as 
required.  When a replacement subject is required, the Sponsor or designee needs to be 
contacted prior to dosing the replacement supplies.
Table 10Product Descriptions
Product Name 
& PotencyDosage Form Source/Additional Information
MK- 5160, 20.0 mg/mL Sterile Solution for IV 
Administration, 1.0 mL 
per vialSupplied by  Sponsor
All supplies indicated inTable 10will be provided per the “Source/Additional Information” 
column depending on local country  operational requirements .
Any commercially  available product not included inTable 10will be provided by the trial 
site, subsidiary  or designee .Every  attempt shoul d be made to source these supplies from a 
single lot/batch number. The trial site is responsible for recording the lot number, 
manufacturer, and expiry  date for any locally  purchased product as per local guidelines 
unless otherwise instructed by  the Sponso r.
Packaging and Labeling Information 9.2
Clinical supplies will be affixed with a clinical label in accordance with regulator y 
requirements.
Subjects will receive open label vials .No kitting is required .
Clinical Supplies Disclosure 9.3
The emergency  unblinding call center will use the randomization schedule for the trial to unblind 
subjects and to unmask treatment identity. The Sponsor will not provide random code/disclosure 
envelopes or lists with the clinical supplies.
Storage and Handling Requirements 9.4
Clinica l supplies must be stored in a secure, limited -access location under the storage 
conditions specified on the label.  
Receipt and dispensing of trial medication must be recorded by an authorized person at the 
trial site.
Clinical supplies may  not be used f or any  purpose other than that stated in the protocol.
Discard/Destruction/ Returns and Reconciliation 9.5
The investigator is responsible for keeping accurate records of the clinical supplies received 
from the Sponsor or designee, the amount dispensed to and returned by the subjects and the 
amount remaining at the conclusion of the trial. For all trial sites, the local country  Sponsor 
personnel or designee will provide appropriate documentation that must be completed for 
drug accountability  and return, or local discard and destruction if appropriate.  Where local 
discard and destruction is appropriate, the investigator is responsible for ensuring that a local 
discard/destruction procedure is documented . 
  04M9RT 
  04W8J9
Product:   MK-5160 66
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidential10.0 ADMINISTRATIVE AND R EGULATORY DETAILS
Confidentiality 10.1
Confidentiality of Data 10.1.1
By signing this protocol, the investigator affirms to the Sponsor that information furnished to 
the investigator by the Sponsor will be maintained in confidence, and such information will 
be divulged to the institutional review board, ethics review committee (IRB/ERC) or similar 
or expert committee; affiliated institution and employ ees, only under an appropriate 
understanding of confidentiality  with such board or committee, affiliated institution and 
employ ees.  Data generated by this trial will be considered confidential by the investigator, 
except to the extent that it is included in a publication as provided in the Publications section 
of this protocol.
Confidentiality of Subject Records 10.1.2
By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/ERC, or regulatory  authority  representatives may consult and/or copy  trial documents in 
order to verify  worksheet/case report form data.  By signing the consent form, the subject 
agrees to this proces s.  If trial documents will be photocopied during the process of verify ing 
worksheet/case report form information, the subject will be identified by unique code only; 
full names/initials will be masked prior to transmission to the Sponsor.
By signing this protocol, the investigator agrees to treat all subject data used and disclosed in 
connection with this trial in accordance with all applicable privacy laws, rules and 
regulations.
Confidentiality of Investigator Information 10.1.3
By signing this protocol, the investigator recognizes that certain personal identify ing 
information with respect to the investigator, and all subinvestigators and trial site personnel, 
may be used and disclosed for trial management purposes, as part of a regulatory  
submissions, and as re quired b y law.  This information may include:
1.name, address, telephone number and e -mail address;
2.hospital or clinic address and telephone number;
3.curriculum vitae or other summary  of qualifications and credentials; and
4.other professional docum entation.
Consistent with the purposes described above, this information may be transmitted to the 
Sponsor, and subsidiaries, affiliates and agents of the Sponsor, in your country  and other 
countries, including countries that do not have laws protecting such information.  
Additionally , the investigator’s name and business contact information may be included 
when reporting certain serious adverse events to regulatory  authorities or to other 
investigators.  By signing this protocol, the investigator expressly consents to these uses and 
disclosures. 
  04M9RT 
  04W8J9
Product:   MK-5160 67
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialIf this is a multicenter trial, in order to facilitate contact between investigators, the Sponsor 
may share an investigator’s name and contact information with other participating 
investigators upon request.
Confide ntiality of IRB/IEC Information 10.1.4
The Sponsor is required to record the name and address of each IRB/IEC that reviews and 
approves this trial.  The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements by requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory  agency  review upon request b y those agencies.
Compliance with Financial Disclosure Requirements 10.2
Financial Disclosure requirem ents are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by Clinical Investigators (21 CFR Part 54).  It is the 
Sponsor's responsibility to determine, based on these regulations, whether a request for 
Financial Disclosure information is required.  It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.  
The investigator/subinvestigator(s) agree, if requested by the Sponsor in accordance with 21 
CFR Part 54, to provide his/her financial in terests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements.  
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by 
the Sponsor . The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the United States for these purposes.  This may involve the 
transmission of information to countries that do not have laws protecting personal data.
Compliance with Law, Audit and Debarment 10.3
By signing this protocol, the investigator agrees to conduct the trial in an efficient and 
diligent manner and in conformance with this protoc ol; generall y accepted standards of Good 
Clinical Practice (e.g., International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice: 
Consolidated Guideline and other generally  accep ted standards of good clinical practice); and 
all applicable federal, state and local laws, rules and regulations relating to the conduct of the 
clinical trial.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scien tific conduct of clinical investigations sponsored by  Merck, is provided in Section 12.1 -
Merck Code of Conduct for Clinical Trials .
The investigator also agrees to allow monitoring, audits, IRB/IEC review and regulatory  
authority  inspection of trial- related documents and procedures and provide for direct access 
to all trial -related source data and documents.
The investigator agrees not to seek reimbursement from subjects, their insurance providers or 
from government programs for procedures included as part of the trial reimbursed to the 
investigator b y the Sponsor. 
  04M9RT 
  04W8J9
Product:   MK -5160 68
Protocol/Amendment No.: 002-00 
MK-5160-002- 00 Final Protocol 27-Feb-2017
ConfidentialThe investigator shall prepare and maintain complete and accurate trial documentation in 
compliance with Good Clinical Practice standards and applicable federal, state and local 
laws, rules and regulations; and, for each subject participating in the trial, provide all data, 
and, upon completion or termination of the clinical trial, submit any other reports to the 
Sponsor as required by  this protocol or as otherwise required pursuant to any  agreem ent with 
the Sponsor.
Trial documentation will be promptly  and fully disclosed to the Sponsor by the investigator 
upon request and also shall be made available at the trial site upon request for inspection, 
copy ing, review and audit at reasonable times by representatives of the Sponsor or any 
regulatory  authorities.  The investigator agrees to promptly  take any  reasonable steps that are 
requested b y the Sponsor as a result of an audit to cure deficiencies in the trial documentation 
and worksheets/case repor t forms.
The investigator must maintain copies of all documentation and records relating to the 
conduct of the trial in compliance with all applicable legal and regulatory  requirements.  This 
documentation includes, but is not limited to, the protocol, worksheets/c ase report forms, 
advertising for subject participation, adverse event reports, subject source data, 
correspondence with regulatory  authorities and IRBs/ERCs, consent forms, investigator’s 
curricula vitae, monitor visit logs, laboratory  reference ranges, 
laboratory  certification or 
quality  control procedures and laboratory  director curriculum vitae.  By  signing this protocol, 
the investigator agrees that documentation shall be retained until at least 2 years after the last 
approval of a marketing applicatio n in an ICH region or until there are no pending or 
contemplated marketing applications in an ICH region or until at least 2 years have elapsed 
since the formal discontinuation of clinical development of the investigational product.  
Because the clinical development and marketing application process is variable, it is 
anticipated that the retention period can be up to 15 years or longer after protocol database 
lock. The Sponsor will determine the minimum retention period and notify  the investigator 
when documents may be destro yed.  The Sponsor will determine the minimum retention 
period and upon request, will provide guidance to the investigator when documents no longer 
need to be retained.  The Sponsor also recognizes that documents may  need to be retained for 
a longer period if required by local regulatory  requirements. All trial documents shall be 
made available if required by relevant regulatory  authorities. The investigator must consult 
with and obtain written approval b y the Sponsor prior to destro ying 
trial and/or subject files.  
ICH Good Clinical Practice guidelines recommend that the investigator inform the subject’s 
primary  physician about the subject’s participation in the trial if the subject has a primary  
physician and if the subject agrees to th e primary  physician being informed.
The investigator will promptly  inform the Sponsor of any regulatory  authority  inspection 
conducted for this trial.
Persons debarred from conducting or working on clinical trials by any court or regulatory 
authority  will not be allowed to conduct or work on this Sponsor’s trials.  The investigator 
will immediately  disclose in writing to the Sponsor if any person who is involved in 
conducting the trial is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
In the event the Sponsor prematurel y terminates a particular trial site, the Sponsor will 
promptly  notify  that trial site’s I RB/IEC. 
  04M9RT 
  04W8J9
Product:   MK-5160 69
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialAccording to European legislation, a Sponsor must designate an overall coord inating 
investigator for a multi -center trial (including multinational).  When more than one trial site 
is open in an EU country, Merck, as the Sponsor, will designate, per country , a national 
principal coordinator (Protocol CI), responsible for coordinati ng the work of the principal 
investigators at the different trial sites in that Member State, according to national 
regulations.  For a single -center trial, the Protocol CI is the principal investigator.  In 
addition, the Sponsor must designate a principal or coordinating investigator to review the 
trial report that summarizes the trial results and confirm that, to the best of his/her 
knowledge, the report accuratel y describes the conduct and results of the trial [Clinical Study  
Report (CSR) CI].  The Spons or may consider one or more factors in the selection of the 
individual to serve as the Protocol CI and or CSR CI (e.g., availabilit y of the Protocol/CSR 
CI during the anticipated review process, thorough understanding of clinical trial methods, 
appropriate enrollment of subject cohort, timely achievement of trial milestones).  The 
Protocol CI  must be a participating trial investigator.
Compliance with Trial Registration and Results Posting Requirements 10.4
Under the terms of the Food and Drug Administration Ame ndments Act (FDAAA) of 2007 
and the European Medicines Agency  (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the trial is solely  responsible for determining whether the trial and its results are subject to 
the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries.  Merck, as Sponsor of this trial, will 
review this protocol and submit the information necessary  to fulfill these requirements. 
Merck entries are not limited to FDAAA or the EMA clinical trial directive mandated trials.  
Information posted will allow subjects to identify  potentiall y appropriate trials for their 
disease conditions and pursue participation by calling a central contact number for further 
information on appropri ate trial locations and trial site contact information.  
By signing this protocol, the investigator acknowledges that the statutory  obligations under 
FDAAA, the EMA clinical trials directive or other locall y mandated registries are that of the 
Sponsor and agrees not to submit any information about this trial or its results to those 
registries.
Quality Management System 10.5
By signing this protocol, the Sponsor agrees to be responsible for implementing and 
maintaining a quality  management system with written development procedures and 
functional area standard operating procedures (SOPs) to ensure that trials are conducted and 
data are generated, documented, and reported in compliance with the protocol, accepted 
standards of Good Clinical Practice, and all appl icable federal, state, and local laws, rules and 
regulations relating to the conduct of the clinical trial.
Data Management 10.6
The investigator or qualified designee is responsible for recording and verify ing the accuracy 
of subject data.  By signing this protocol, the investigator acknowledges that his/her 
electronic signature is the legall y binding equivalent of a written signature.  By enterin g 
his/her electronic signature, the investigator confirms that all recorded data have been 
verified as accurate. 
  04M9RT 
  04W8J9
Product:   MK-5160 70
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialDetailed information regarding Data Management procedures for this protocol will be 
provided separatel y.
Publications 10.7
This trial is intended for publication, even if terminated prematurel y. Publication may include 
any or all of the following: posting of a synopsis online, abstract and/or presentation at a 
scientific conference, or publication of a full manuscript.  The Sponsor will work with the 
authors to submit a manuscript describing trial results within 12 months after the last data 
become available, which may take up to several months after the last subject visit in some 
cases such as vaccine trials.  However, manuscript submission timelines may  be extended on 
OTC trials.  For trials intended for pediatric -related regulatory  filings, the investigator agree s 
to delay  publication of the trial results until the Sponsor notifies the investigator that 
all 
relevant regulatory  authority  decisions on the trial drug have been made with regard to 
pediatric -related regulatory  filings. Merck will post a synopsis of trial results for approved 
products on www.clinicaltrials.gov by 12 months after the last subject's last visit for the 
primary  outcome, 12 months after the decision to discontinue development, or product 
marketing (dispensed, administered, delivered or promot ed), whichever is later.
These timelines may be extended for products that are not yet marketed, if additional time is 
needed for analysis, to protect intellectual property , or to compl y with confidentiality 
agreements with other parties.  Authors of the primary  results manuscript will be provided 
the complete results from the Clinical Study  Report, subject to the confidentiality  agreement. 
When a manuscript is submitted to a biomedical journal, the Sponsor's policy  is to also 
include the protocol and statistical analy sis plan to facilitate the peer and editorial review of 
the manuscript.  If the manuscript is subsequently accepted for publication, the Sponsor will 
allow the journal, if it so desires, to post on its website the key sections of the protocol that 
are relevant to evaluating the trial, specifically  those sections describing the trial objectives 
and hypotheses, the subject inclusion and exclusion criteria, the trial design and procedures, 
the efficacy  and safet y measures, the statistical analy sis plan, and any  amendments relating to 
those sections.  The Sponsor reserves the right to redact proprietary information.
For multicenter trials, subsequent to the multicenter publication (or after public disclosure of 
the results online at www.clinicaltrial s.gov if a multicenter manuscript is not planned), an 
investigator and his/her colleagues may publish their data independentl y.  In most cases, 
publication of individual trial site data does not add value to complete multicenter results, 
due to statistical concerns.  In rare cases, publication of single trial site data prior to the main 
paper may be of value.  Limitations of single trial site observations in a multicenter trial 
should alway s be described in such a manuscript.
Authorship credit should be bas ed on 1) substantial contributions to conception and design, 
or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising 
it critically  for important intellectual content; and 3) final approval of the version to be 
published. Authors must meet conditions 1, 2 and 3.  Significant contributions to trial 
execution may also be taken into account to determine authorship, provided that 
contributions have also been made to all three of the preceding authorship criteria.  Although 
publication planning may  begin before conducting the trial, final decisions on authorship and 
the order of authors’ names will be made based on participation and actual contributions to  
  04M9RT 
  04W8J9
Product:   MK -5160 71
Protocol/Amendment No.: 002-00 
MK-5160-002- 00 Final Protocol 27-Feb-2017
Confidentialthe trial and writing, as discussed above. The 
first author is responsible for defending the 
integrit y of the data, method(s) of data anal ysis and the scientific content of the manuscript.
The Sponsor must have the opportunity  to review all proposed abstracts, manuscripts or 
presentations regarding this trial 45days prior to submission for publication/presentation. 
Any information identified by the Sponsor as confidential must be deleted prior to 
submission; this confidentiality  does not include efficacy  and safety  results. Sponsor review 
can be expedited to meet public ation timelines.
11.0 LIST OF REFERENCES
1.Heise et al. Expert Opin. Drug Metab. Toxicol 2015, 11:1193 -1201.
2. Sinha VP et al DOM 2013, 16: 344-350
3. Bergenstal RM et al DOM 2016, 18: 1081-1088
4. Blevins T et al DOM 2016, 18: 1072-1080
5.Rizza RA, Mandarino LJ, Gerich JE. Dose -response characteristics for effects of insulin 
on production and utilization of glucose in man. Am. J. Physiol. 1981; 193: E630-639.
6.Argoud GM, Schade DS, Eaton RP. Underestimation of hepatic glucose production by 
radioactive and stable tracers. Am. J. Phy siol. 1987; 252: E606 -615.
7.Henry  RR, Mudaliar S, Ciaraldi TP, Armstrong DA, Burke P, Pettus J, Garh yan P, Choi 
SL, Jacober SJ, Knadler MP, Lam ECQ, Prince MJ, Bose N, Porksen N, Sinha VP, 
Linnebjerg H. Basal insulin peglispro demonstrates prefere ntial hepatic versus peripheral 
action relative to insulin glargine in health y subjects. Diabetes Care 2014; 37: 2609 -2615. 
  04M9RT 
  04W8J9
Product:   MK-5160 72
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidential12.0 APPENDICES
Merck Code of Conduct for Clinical Trials 12.1
Merck *
Code of Conduct for Clinical Trials
I. Introduction
A. Purpose
Merck, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials in 
compliance with the highest ethical and scientific standards. Protection of subject safety is the overriding concern in 
the design of clinical trials. In all cases, Merck clinical trials will be conducted in compliance with local and/or 
national regulations and in accordance with the ethical principles that have their origin in the Declaration of Helsinki. 
B. Scope
Such standards shall be endorsed for all clinical interventional investigations sponsored by Merck irrespective of the 
party (parties) employed for their execution (e. g., contract research organizations, collaborative research efforts). This 
Code is not intended to apply to trials which are observational in nature, or which are retrospective. Further, this Code 
does not apply to investigator -initiated trials which are n ot under the control of Merck.
II.Scientific Issues
A. Trial Conduct
1.Trial Design
Except for pilot or estimation trials, clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of Merck or comparator products.  Alternatively, Merck may 
conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine 
subject preferences, etc.  
The design (i.e., subject population, duration, statistical power) must be adequate to address the specific purpose 
of the trial.  Research subjects must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
Merck selects investigati ve sites based on medical expertise, access to appropriate subjects, adequacy of facilities 
and staff, previous performance in Merck trials, as well as budgetary considerations.  Prior to trial initiation, sites 
are evaluated by Merck personnel to assess t he ability to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Trial sites are monitored to assess compliance with the trial protocol and general principles of Good Clinical 
Practice.  Merck reviews clinical data for accuracy, comple teness and c onsistency. Data are verified versus source 
documentation according to standard operating procedures.  Per Merck policies and procedures, if fraud, 
misconduct or serious GCP -non-Compliance are suspected, the issues are promptly investigated. When necessary, 
the clinical site will be closed, the responsible regulatory authorities and ethics review committees notified and 
data disclosed accordingly. 
B. Publication and Authorship
To the extent scientifically appropriate, Merck seeks to publish theresults of trials it conducts.  Some early phase or 
pilot trials are intended to be hypothesis -generating rather than hypothesis testing.  In such cases, publication of 
results may not be appropriate since the trial may be underpowered and the analyses complicated by statistical issues 
of multiplicity.
Merck’s policy on authorship is consistent with the requirements outlined in the ICH-Good Clinical Practice 
guidelines. In summary, authorship should reflect significant contribution to the design and conduc t of the trial, 
performance or interpretation of the analysis, and/or writing of the manuscript.  All named authors must be able to 
defend the trial results and conclusions.  Merck funding of a trial will be acknowledged in publications.  
  04M9RT 
  04W8J9
Product:   MK -5160 73
Protocol/Amendment No.: 002-00 
MK-5160-002- 00 Final Protocol 27-Feb-2017
ConfidentialIII
.Subject Prot ection
A.IRB/ERC review
All clinical trials will be reviewed and approved by an independent IRB/ERC before being initiated at each site.  
Significant changes or revisions to the protocol will be approved by the IRB/ERC prior to implementation, except that
changes required urgently to protect subject safety and well-being may be enacted in anticipation of IRB/ERC 
approval. For each site, the IRB/ERC and Merck will approve the subject informed consent form. 
B.Safety
The guiding principle in decision -making in clinical trials is that subject welfare is of primary importance.  Potential 
subjects will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial 
designs will take into account the local standard of care.  Subjects are never denied access to appropriate medical care 
based on participation in a Merck clinical trial. 
All participation in Merck clinical trials is voluntary.  Subjects are enrolled only after providing informed consent for 
participatio n.  Subjects may withdraw from a Merck trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C.Confidentiality
Merck is committed to safeguarding subject confidentiality, to the greatest extent possible.  Unless required by law, 
only the investigator, Sponsor (or representative) and/or regulatory authorities will have access to confidential medical 
records that might identify the research subject by name.  
D.Genomic Research
Genomic Research will only be conducted in accordance with informed consent and/or as specifically authorized by 
an Ethics Committee.
IV.Financial Considerations
A.Payments to Investigators
Clinical trials are time- and labor-intensive.  It is Merck’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performe d in support of Merck trials.  Merck does not pay incentives to 
enroll subjects in its trials.  However, when enrollment is particularly challenging, add itional payments may be made 
to compensate for the time spent in extra recruiting efforts.
Merck does not pay for subject referrals.  However, Merck may compensate referring physicians for time spent on 
chart review to identify potentially eligible subject s.
B.Clinical Research Funding 
Informed consent forms will disclose that the trial is sponsored by Merck, and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial.  However, the local IRB/ERC may wish to alter 
the wording of the disclosure statement to be consistent with financial practices at that institution.  As noted above, 
publications resulting from Merck trials will indicate Merck as a source of funding.
C.Funding for Travel and Other Requests
Funding of travel by investigators and support staff (e.g.,to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices including, in the U.S., those established by the American Medical 
Association (AMA). 
V.Investigator Commit ment
Investigators will be expected to review Merck’s Code of Conduct as an appendix to the trial protocol, and in signing 
the protocol, agree to support these ethical and scientific standards.
* In this document, "Merck" refers to Merck Sharp & Dohme Corp. and Schering Corporation, each of which is a 
subsidiary of Merck & Co., Inc.  Merck is known as MSD outside of the United States and Canada.  As warranted by 
context, Merck also includes affiliates and subsidiaries of Merck & Co., Inc." 
  04M9RT 
  04W8J9
Product:   MK-5160 74
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialCollection and Management of Specimens for Future Biomedical Research 12.2
1.Definitions
a.Biomarker:  A biological molecule found in blood, other body  fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or disease.  A biomarker may be 
used to see how well the body  responds to a treatment for a disease or condition.1
b.Pharmacogenomics:  The investigation of variations of DNA and RNA characteristics as 
related to drug /vaccine response.2
c.Pharmacogenetics:  A subset of pharmacogenomics, pharmacogenetics is the influence of 
variations in DNA sequence on drug /vaccine response.2
d.DNA:  Deox yribonucleic acid.
e.RNA:  Ribonucleic acid.
2.Scope of Future Biomedical Research
The specimens consented and/or collected in this trial as outlined in Section 7.1.3.4 –
Future Biomedical Research Samples will be used in various experiments to understand:
oThe biology  of how drugs/vaccines work
oBiomarkers responsible for how a drug/vaccine enters and is removed b y the body
oOther pathway s drugs/vaccines may  interact with
oThe biology  of disease
The specimen(s) may be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that information obtained from study ing and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs /vaccines , enhance our understanding of human disease and ultimately 
improve public health through development of novel treatments targeted to populations 
with the greatest need.  All specimens will be used by the Sponsor or those working for 
or with the Sponsor .
3.Summary of Procedures for Future Biomedical Research
a.Subjects for Enrollment
All subjects enrolled in the clinical trial will be considered forenrollment in the 
Future Biomedical Research sub -trial.
b.Informed Consent
Informed consent for specimens (i.e., DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all subjects or legal guardians, at a trial 
visit by the investigator or his or her designate.  Informed consent for Future 
Biomedical Research should be presented to the subjects on the visi t designated in the 
trial flow chart .  If delayed, present consent at next possible Subject Visit.   Consent 
forms signed by the subject will be kept at the clinical trial site under secure storage 
for regulatory  reasons.   
  04M9RT 
  04W8J9
Product:   MK -5160 75
Protocol/Amendment No.: 002-00 
MK-5160-002- 00 Final Protocol 27-Feb-2017
ConfidentialA template of each trial site’s approved informed 
consent will be stored in the 
Sponsor’s clinical document repository .
c.eCRF Documentation for Future Biomedical Research Specimens
Documentation of subject consent for Future Biomedical Research will be captured in 
the electronic Case Report Forms (eCRFs). Any specimens for which such an 
informed consent cannot be verified will be destroy ed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for Future Biomedical Research will be performed as 
outlined in the trial flow chart. In general, if additional blood specimens are being 
collected for Future Biomedical Research, these will usually  be obtained at a time 
when the subject is having blood drawn for other trial purposes.
4. C onfidential Subject Information for Future Biomedical Research 
In order to optimize the research that can be conducted with Future Biomedical Research 
specimens, it is critical to link subject' clinical information with fu ture test results. In fact 
little or no research can be conducted without connecting the clinical trial data to the 
specimen. The clinical data allow specific analy ses to be conducted. Knowing subject 
characteristics like gender, age, medical history  and treatment outcomes are critical to 
understanding clinical context of analy tical results.
To maintain privacy  of information collected from specimens obtained for Future 
Biomedical Research, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below . 
At the clinical trial site, unique codes will be placed on the Future Biomedical Research 
specimens.  This code is a random number which does not contain any personall y 
identify ing information embedded within it. The link (or key) between subject identifiers 
and this unique code will be held at the trial site.  No personal identifiers will appear on 
the specimen tube.  
5.Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for analyses using good scientific 
practices.  Anal yses utilizing the Future Biomedical Research specimens may be 
performed by the Sponsor , or an additional third party (e.g., a university  investigator) 
designated by the Sponsor . The investigator conducting the analy sis will follow the 
Sponsor’s privacy  and confidentiality  requirements. Any contracted third party  analyses 
will conform to the specific scope of anal ysis outlined in this sub- trial. Future Biomedical 
Research specimens remai ning with the third party  after specific analy sis is performed 
will be reported to the Sponsor .
6. Withdrawal From Future Biomedical Research 
Subjects may withdraw their consent for Future Biomedical Research and ask that their 
biospecimens not be used for Future Biomedical Research.   Subjects may withdraw 
consent at any time by contacting the principal investigator for the main trial. If medical 
records for the main trial are still available, the investigator will contact the Sponsor 
using the designated mailbox   
  04M9RT
PPD 
  04W8J9
Product:   MK -5160 76
Protocol/Amendment No.: 002-00 
MK-5160-002- 00 Final Protocol 27-Feb-2017
ConfidentialSubsequently , the subject's specimens will be flagged in the biorepository and restricted 
to main study  use only. If specimens were collected from study  participants specificall y 
for Future Biomedical Resea rch, these specimens will be removed from the biorepository  
and destro yed. Documentation will be sent to the investigat or confirming withdrawal 
and/or destruction, if applicable. It is the responsibility  of the investigator to inform the 
subject of complet ion of the withdrawal and/or destruction, if applicable.  Any analyses 
in progress at the time of request for withdrawal/destruction or already  performed prior to 
the request being received by the Sponsor will continue to be used as part of the overall 
research trial data and results. No new analy ses would be generated after the request is 
received.
In the event that the medical records for the main trial are no longer available (e.g., if the 
investigator is no longer required by regulatory  authorities to retain the main trial 
records) or the specimens have 
been completel y anony mized, there will no longer be a 
link between the subject’s personal information and their specimens. In this situation, the 
request for withdrawal of consent and/or destruction canno t be processed.
7. Retention of Specimens 
Future Biomedical Research specimens will be stored in the biorepository  for potential 
analysis for up to 20 years from the end of the main study . Specimens may be stored for 
longer if a regulatory  or governmenta l authority  has active questions that are being  
answered. In this special circumstance, specimens will be stored until these questions 
have been adequatel y addressed.
Specimens from the trial site will be shipped to a central laboratory  and then shipped to
the Sponsor -designated biorepository . If a central laboratory  is not utilized in a particular 
trial, the trial site will ship directly  to the Sponsor -designated biorepository . The 
specimens will be stored under strict supervision in a limited access facility which 
operates to assure the integrity  of the specimens.  Specimens will be destroy ed according 
to Sponsor policies and procedures and this destruction will be documented in the 
biorepository  database.
8.Data Security
Databases containing specimen information and test results are accessible only to the 
authorized Sponsor representatives and the designated trial administrator research 
personnel and/or collaborators. Database user authentication is highly secure, and is 
accomplished using network security policies and practices based on international 
standards to protect against unauthorized access.
9. Reporting of Future Biomedical Research Data to Subjects
No information obtained from exploratory  laboratory  studies will be reported to the 
subject, family, or physicians.
Principle reasons not to inform or return results to the 
subject include: Lack of relevance to subject health, limitations of predictive capability , 
and concerns regarding misinterpretation.
If important research findings are discovere d, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapidly  report this information to doctors and subjects.  Subjects will not be identified by  
  04M9RT 
  04W8J9
Product:   MK -5160 77
Protocol/Amendment No.: 002-00 
MK-5160-002- 00 Final Protocol 27-Feb-2017
Confidentialname in any published reports about this study  or in any other scientific publication or 
presentation.
10. Future Biomedical Research Study Population
Every  effort will be made to recruit all subjects diagnosed and treated on Sponsor clinical 
trials for Future Biomedical Research .
11.Risks Versus Benefits of Future Biomedical Research 
For future biomedical research, risks to the subject have been minimized. No additional 
risks to the subject have 
been identified as no additional specimens are being collected 
for Future Biomedical Res earch (i.e., onl y leftover samples are being retained).
The Sponsor has developed strict security, policies and procedures to address subject data 
privacy  concerns.  Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentiality .  In this highly unlikely  situation there is risk that the 
information, like all medical information, may  be misused.
12.Questions
Any questions related to the future biomedical research should be e-mailed directl y to 
.
13.References
1. National Cancer Institute: http://www.cancer.gov/dictionary /?searchTxt=biomarker
2.International Conference on Harmonization: DEFIN ITIO NS FOR GENOMIC 
BIOMARKERS, PHARMACOGENOMICS, 
PHARMACOGENETICS, GENOMIC 
DATA AND SAMPL E CODING CATEGORIES - E15; 
http://www.ich.org/LOB/media/MEDIA3383.pdf
3.Industry  Pharmacogenomics Working Group. Under standing the Intent, Scope and 
Public Health Benefits of Exploratory  Biomarker Research: A Guide for IRBs/IECs 
and Investigational Site Staff. Available at http://i -pwg.org/
4.Industry  Pharmacogenomics Working Group. Pharmacogenomics Informational 
Brochur e for IRBs/IECs and Investigational Site Staff. Available at http://i -pwg.org/ 
  04M9RT
PPD 
  04W8J9
 
  04W8J9
Product:   MK-5160 79
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidential12-Lead Electrocardiogram Abnormality Criteria 12.4
12-Lead Electrocardiogram Abnormality Criteria 
Screen Failure Criteriaa Potentially Significant Post -Randomization 
Findings (clarification on action to take)b
RHYTHM
Sinus Tachycardia 110 bpmHR >110 bpm  and HR increase of ≥ 25 bpm 
from baseline 
Sinus Bradycardia < 40 bpmHR < 40 bpm and HR decrease of ≥ 5 bpm
from baseline
Sinus Pause/Arrest > 2.0 seconds > 2.0 seconds
Atrial premature 
complex1 beat 3 beats
Ventricular premature 
complexAll 3 beats
Ectopic Atrial Rhythm None None
Junctional Rhythm Junctional Rhythm with HR < 40 bpm Junctional Rhythm with HR < 40 bpm
Idioventricular Rhythm All All
Atrial Fibrillation All All
Atrial Flutter All All
Supraventricular 
TachycardiaAll All
Ventricular Tachycardia All All
AXIS
Left Axis Deviation RBBB with Left Anterior Hemiblock (LAHB) New onset LAHB
Right Axis Deviation RBBB with Left Posterior Hemiblock (LPHB) New onset LPHB
CONDUCTION
1st degree A -V Block PR 230 msPR 230 ms + increase of 15 ms; or PR 
increase of > 25%
2nd degree A -V Block Mobitz Type II Mobitz Type II
3rd degree A -V Block All All
LBBB   All All
RBBB   RBBB with LAHB/LPHB as defined aboveNew onset RBBB (not including intermittent 
or rate -related)
Incomplete Right BBB 
(ICRBBB) (QRS<120 
ms)No exclusion Nothing
Short PR/ Preexcitation 
syndromeDelta wave + PR <120 ms Delta wave + PR <120 ms
Other Intra -ventricular 
Conduction DelayQRS 130 ms QRS 130 ms + increase of 10 ms
QTc (B or F)
Male QTc 450 msQTc 500 ms or increase of 60 ms from 
baseline
Female QTc 450 msQTc 500 ms or increase of 60 ms from 
baseline
HYPERTROPHY
Atrial abnormalities Definite evidence of P mitrale or P pulmonaleDefinite evidence of P mitrale or P 
pulmonale 
  04M9RT 
  04W8J9
Product:   MK -5160 80
Protocol/Amendment No.: 002-00 
MK-5160-002- 00 Final Protocol 27-Feb-2017
Confidential12
-Lead Electrocardiogram Abnormality Criteria 
Screen Failure Criteriaa Potentially Significant Post -Randomization 
Findings (clarification on action to take)b
Ventricular abnormalities Voltage criteria for LVH plus Strain Pattern Voltage criteria  for LVH plus Strain Pattern
MYOCARDIAL  INFARCTION
Acute or Recent All All
Old All All
ST/T MORPHOLOGY
ST elevation suggestive 
of Myocardial Injury In 2 or more contiguous leads In 2 or more contiguous leads
ST depression 
suggestive of
Myocardial Ischaemia In 2 or more contiguous  leads In 2 or more contiguous  leads
T-wave Inversions 
suggestive of  
Myocardial Ischaemia In 2 or more contiguous  leads In 2 or more contiguous leads
Non-specific ST -T 
changes 
(In 2 or more leads)No exclusion In 2 or more contiguous leads
PACEMAKER All All
Baseline is defined as Predose Day 1
ms=milliseconds, mm=millimeter
a Abnormalities noted, but not considered clinically significant should be discussed with Sponsor prior to dosing.
bPost-randomization assessments are at each specified timepoint. Discussion between the investigator and sponsor should 
occur if abnormalities are noted. 
  04M9RT 
  04W8J9
Product:   MK -5160 81
Protocol/Amendment No.: 002-00 
MK-5160-002- 00 Final Protocol 27-Feb-2017
ConfidentialQTc Stopping Criteria:
1. 
Confirmed increase in absolute QTc ≥500 ms 
If the QTc interval is 500 msec, the Sponsor should be notified and the ECGs should be 
reviewed b y a cardiologist. The subject should be telemetry -monitored (until the QTc is <500 
msec) or should be considered for transfer to a location where closer monitoring and 
definitive care (e .g., a Cardiac or Intensive Care Unit) is available.
2. 
Confirmed increase in QTc from baseline of  ≥60 ms
During each treatment period, if a subject demonstrates an increase in QTc interval ≥60 msec 
compared with mean predose baseline measurement, the ECG will be repeated twice within 5 
minutes.  The meanvalue of the QTc interval from the 3 ECGs will represent the value at 
that time point.  If the average QTc interval increase from baseline for any postdose time 
point is ≥60 msec, the subject will continu
e to be monitored by repeat 12-lead ECGs every 
15 minutes for at least 1 hour or until the QTc is within 60 msec of baseline.  If prolongation 
of the QTc interval ≥60 msec persists, a consultation with a study  cardiologist may be 
appropriate and the Sponso r should be notified. 
  04M9RT 
  04W8J9
Product:   MK-5160 82
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialAlgorithm for Assessing Out -of-Range Laboratory Values 12.5
For all laboratory  values obtained at prestud y (screening) visit and/or pre -dose evaluation:
A.If all protocol- specified laboratory  values are normal, the subject may  enter the study .
B.If a protocol -specified laboratory  value is outside of the parameter(s) outlined in the 
inclusion/exclusion criteria (including a repeat if performed), the subject will be excluded 
from the study .
C.If ≥1 protocol -specified laboratory  value notspecified in the inclusion/exclusion criteria 
is outside the normal range, the following choices are available:
1.The subject may  be excluded from the stud y;
2.The subject may be included in the study  if the abnormal value(s) is not clinically 
significant (NCS) (the investigator must annotate the laboratory  value “NCS” on the 
laboratory  safet y test source document).
3.The subject may be included in the study  if the abnormality  is consistent with a pre-
existing medical condition which is not excluded per protocol (e.g., elevated 
eosinophil count in a subject with asthma or seasonal allergies) the medical condition 
should be annotated on the laboratory  report or
4.The abnormal test may be repeated (refer items a. and b. below for continuation of 
algorithm for repeated values).
a.If the repeat test value is within the normal range, the subject may enter the study.
b.If the repeat test value is still abnormal, the study  investigator will evaluate the 
potential subject with a complete history  and physical examination, looking 
especiall y for diseases that could result in the abnormal laboratory  value in 
question.  If such diseases can be ruled out, and if the abnormal laboratory  value 
is not clinically  relevant, then the subject may  enter the study .
D.If there is any clinical uncertaint y regarding the significance of an abnormal value, the 
subject will be excluded from the study . 
  04M9RT 
  04W8J9
Product:   MK-5160 83
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
ConfidentialCriteria for Classifying Documented Episodes of Hyper- or Hypoglycemia as 12.6
Adverse Events 
The following will be used to determine adverse event (AE) reporting in cases of 
hypoglycemia and h ypergl ycemia:
Hypoglycemia is defined as glucose values ≤70 with symptoms and glucose values ≤50 with 
or without sy mptoms.
If there aresymptoms associated with low glucose (≤70), this isa clinical AEwith a 
diagnosis of h ypogl ycemia. 
If there areno symptoms associated with a low glucose (>50 ≤70) it is up to the 
investigator to decide if this is a laboratory AE.  The AE would be decreased 
glucose ,not hy poglycemia.
All glucose values ≤70 will require a comment that states whether or not there were 
associated symptoms of hy poglycemia.
Hypergl ycemia: 
If there are symptoms associated with a high glucose, this is a clinical AE with a diagnosis 
of hyperglycemia.
Fingerstick glucose assessme nt can be performed at any time, at the discretion of the 
Investigator.
Correction of hyper-/hypoglycemia should be initiated as appropriate, at the discretion of the 
Investigator according to the site’s standard operating procedures .  Corrective actions for 
hypoglycemia include, but are not limited to: offering food/drink, IV dextrose bolus, and 
initiating or increasing the rate of a running IV dextrose infusion.   Corrective actions for 
hypergly cemia include, but are not limited to: bolus SC injection of short -acting insulin, 
initiation or increase in the rate of a SC infusion of short -acting insulin, and initiation or 
increase in the rate of an IV infusion of insulin.  The dose and/or frequency  of MK-
5160/glargine should not be chang ed for h yperglycemia. 
  04M9RT 
  04W8J9
Product:   MK-5160 84
Protocol/Amendment No.: 002-00 
MK-5160 -002-00 Final Protocol 27-Feb-2017
Confidential13.0 SIGNATURES
Sponsor's Representative 13.1
TYPED NAME
TITLE
SIGNATURE
DATE SIGNED
Investigator 13.2
I agree to conduct this clinical trial in accordance with the design outlined in this protocol 
and to abide by all provisions of this protocol (including other manuals and documents 
referenced from this protocol).  I  agree to conduct the trial in accordance with generally 
accepted standards of Good Clinical Practice.  I also agree to report all information or data in 
accordance with the protocol and, in particular, I agree to report any serious adverse events 
as defined in Section 7.0–TRIAL PROCEDURES (Assessing and Recording Adverse 
Events ).  I also agree to handle all clinical supplies provided by the Sponsor and collect and 
handle all clinical specimens in accordance with the protocol.  I understand that information 
that identifies me will be used and disclosed as described in the protocol, and that such 
information may be transferred to countries that do not have laws protecting such
information.  Since the information in this protocol and the referenced Investigator’s 
Brochure is confidential, I understand that its disclosure to any third parties, other than those 
involved in approval, supervision, or conduct of the trial is prohibit ed.  I will ensure that the 
necessary  precautions are taken to protect such information from loss, inadvertent disclosure 
or access b y third parties.
TYPED NAME
TITLE
SIGNATURE
DATE SIGNED 
  04M9RT 
  04W8J9